



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 184500

TO: Rei-Tsang Shiao
Location: REM-5A10&5C18
Art Unit: 1626
Monday, April 10, 2006

Case Serial Number: 10/792355

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: 571-272-2527

Paul.schulwitz@uspto.gov

Search Notes

Examiner Shiao,

Please review the attached search results.

If you have any questions or if you would like to refine the search query, please feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
REM-1A65
571-272-2527


SEARCH REQUEST FORM

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Earliest Priority Date: _____

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

in such CPI (see also 1.4)



IV each crystalline form of cp I.
III each composition among cpd I.

Vendors and cost where applicable

_____ STN _____ Dialog

Questel/Orbit Lexis/Nexis

_____ Westlaw _____ WWW/Internet

In-house sequence systems

☐ Commercial ☐ Oligomer ☐ Score/Length
☐ Interference ☐ SPDI ☐ Encode/Transl
☐ Other (specify)

Fulltext

Other



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



=> d his ful

(FILE 'HOME' ENTERED AT 10:16:57 ON 10 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:17:25 ON 10 APR 2006

L1 STR
L2 2 SEA SSS SAM L1
D SCA
L3 512 SEA SSS FUL L1
L4 STR L1
L5 3 SEA SUB=L3 SSS SAM L4
D SCAN
L6 76 SEA SUB=L3 SSS FUL L4

FILE 'HCAPLUS' ENTERED AT 10:25:58 ON 10 APR 2006

L7 929 SEA ABB=ON PLU=ON L6

FILE 'REGISTRY' ENTERED AT 10:26:14 ON 10 APR 2006

L8 STR L4
L9 3 SEA SUB=L3 SSS SAM L8
L10 57 SEA SUB=L3 SSS FUL L8

FILE 'HCAPLUS' ENTERED AT 10:36:39 ON 10 APR 2006

L11 928 SEA ABB=ON PLU=ON L10

FILE 'REGISTRY' ENTERED AT 10:37:17 ON 10 APR 2006

L12 STR
L13 1 SEA SUB=L3 SSS SAM L12
D SCA
L14 10 SEA SUB=L3 SSS FUL L12
D SCA

FILE 'HCAPLUS' ENTERED AT 10:40:33 ON 10 APR 2006

L15 80 SEA ABB=ON PLU=ON L14

FILE 'REGISTRY' ENTERED AT 10:40:45 ON 10 APR 2006

L16 4 SEA ABB=ON PLU=ON L14 AND NC<3
D SCA

FILE 'HCAPLUS' ENTERED AT 10:42:02 ON 10 APR 2006

L17 80 SEA ABB=ON PLU=ON L16

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2006 HIGHEST RN 879722-24-4

DICTIONARY FILE UPDATES: 7 APR 2006 HIGHEST RN 879722-24-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2006 VOL 144 ISS 16
FILE LAST UPDATED: 9 Apr 2006 (20060409/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 10:42:22 ON 10 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2006 VOL 144 ISS 16
FILE LAST UPDATED: 9 Apr 2006 (20060409/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

L1

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L3 512 SEA FILE=REGISTRY SSS FUL L1

L12 STR

t-Bu~NH2

1 2

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 2

STEREO ATTRIBUTES: NONE

L14 10 SEA FILE=REGISTRY SUB=L3 SSS FUL L12

L16 4 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND NC<3

L17 80 SEA FILE=HCAPLUS ABB=ON PLU=ON L16

=> d l17 ibib abs hitstr 1-80

L17 ANSWER 1 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:218184 HCAPLUS

DOCUMENT NUMBER: 144:280633

TITLE: Method for treatment of arterial hypertension by administration of medicinal preparations in a biorhythmical sequence

INVENTOR(S): Malov, V. A.; Malova, E. V.

PATENT ASSIGNEE(S): Russia
 SOURCE: Russ., 16 pp.
 CODEN: RUXXE7
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2271197	C2	20060310	RU 2004-111759	20040419
PRIORITY APPLN. INFO.:			RU 2004-111759	20040419

AB FIELD: medicine, therapy. SUBSTANCE: invention relates to a method for treatment of arterial hypertension. Method involves administration of one or some medicinal preps. in a biorhythmical sequence taken among the following order: papaverine, common wormwood tincture - at 7.00 - 9.00 a. m.; thrombo-ACC (sic), rheopro, clopidogrel - at 9.00 - 11.00 a. m.; No-Spa - at 11.00 a. m.; trental - at 11.15 a. m.; atenolol, propranolol, metoprolol, nifedipine, verapamil, cordarone, valerian, motherwort - at 11.30 a. m.; polyvitamins, fenules (sic) - at 1.00 p. m.; No-Spa - at 4.00 p. m.; trental - at 4.15 p. m.; hypothiazid, furosemide, verospiron, captopril, enalapril, prestarium, quinapril, ramipril, losartan, valsartan - at 4.30 p. m.; No-Spa - at 7.00 p. m.; trental - at 7.15 p. m.; atenolol, propranolol, metoprolol, nifedipine, verapamil, cardura, valerian, motherwort, phenazepam, coaxil, paxil - at 7.30 p. m.; ginseng - at 9.00 p. m.; Essentiale, simvastatin, lovastatin - at 11.00 p. m. The method provides recovery of levels synchronization in organization of organ-forming systems that allows to carry out the effect on the arterial pressure value in the corresponding time of day.

IT 107133-36-8, Prestarium
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method for treatment of arterial hypertension by administration of medicinal preps. in a biorhythmical sequence)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0

CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

117 ANSWER 2 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:149722 HCAPLUS

DOCUMENT NUMBER: 144:205780

TITLE: Combination therapy for diabetes, obesity and cardiovascular diseases using growth differentiation factor 8 (GDF-8) inhibitors

INVENTOR(S): Tobin, James F.

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: U.S. Pat. Appl. Publ., 51 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006034831	A1	20060216	US 2005-201825	20050811
PRIORITY APPLN. INFO.:			US 2004-600784P	P 20040812

AB A method of treating obesity, cardiovascular diseases, and disorders of insulin metabolism in a subject, comprising administering to the subject a therapeutically effective amount of a growth differentiation factor 8 (GDF-8, myostatin) inhibitor, and a therapeutically effective amount of at least one other therapeutic agent which treats the targeted syndrome. GDF-8 inhibitors include antibodies (against GDF-8 and/or a GDF-8 receptor, such as activin receptor type IIB (ActRIIB)), modified soluble receptors, other proteins (including those that bind to GDF-8 and/or a GDF-8 receptor), propeptides, peptides and mimetics of all of these inhibitors. Other therapeutic agents listed in claims and include insulin products, sulfonylureas, biguanides, and thiazolidinedione agents, antilipemic agents, alpha-glucosidase inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, aldose reductase inhibitors, and angiotensin converting enzyme (ACE) inhibitors.

IT 107133-36-8, Perindopril-tert-butylamine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ACE inhibitor; combination therapy for diabetes, obesity and cardiovascular diseases using growth differentiation factor 8 (GDF-8) inhibitors)


RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



L17 ANSWER 3 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1311320 HCAPLUS

DOCUMENT NUMBER: 144:7101

TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts

INVENTOR(S): Fugier, Claude; Dubuffet, Thierry; Langlois, Pascal

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1367063	A1	20031203	EP 2003-291931	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2533005	AA	20050210	CA 2004-2533005	20040729
WO 2005012333	A2	20050210	WO 2004-FR2035	20040729
WO 2005012333	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.:

EP 2003-291931

A 20030731

WO 2004-FR2035

W 20040729

OTHER SOURCE(S):

MARPAT 144:7101

AB A method for the synthesis of perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] involves coupling of (2S)-hexahydroindole-2-carboxylic acid or its benzyl ester with (R)-G-CHMeCOCl (G = Cl, Br, OH, tosyloxy, mesyloxy or trifluoromethanesulfonyloxy) and then (S)-Et 2-aminopentanoate, followed by catalytic hydrogenation. In an example, the resp. coupling reactions were carried in CH₂Cl₂-EtNPr-i₂ at room temperature and MeCN-Et₃N at reflux. Yield of perindopril following hydrogenation was 95% (enantiomeric purity 99%).

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(synthesis of perindopril from hexahydroindolecarboxylate and bromopropionyl chloride)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ B17 ANSWER 4 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1311047 HCAPLUS

DOCUMENT NUMBER: 144:7100

TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts.

INVENTOR(S): Fugier, Claude; Dubuffet, Thierry; Langlois, Pascal

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1367062	A1	20031203	EP 2003-291930	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004261440	A1	20050210	AU 2004-261440	20040729
WO 2005012328	A2	20050210	WO 2004-FR2036	20040729
WO 2005012328	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-291930 A 20030731
WO 2004-FR2036 W 20040729

OTHER SOURCE(S): MARPAT 144:7100

AB A method for the synthesis of perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] involves coupling of (2S)-hexahydroindole-2-carboxylic acid or its benzyl ester with (R)-G-CHMeCOCl (G = Cl, Br, OH, tosyloxy, mesyloxy or trifluoromethanesulfonyloxy) and then (S)-Et 2-aminopentanoate, followed by catalytic hydrogenation. In an example, the resp. coupling reactions were carried in CH₂Cl₂-EtNPr-i₂ at room temperature and MeCN-Et₃N at reflux. Yield of perindopril following hydrogenation was 95% (enantiomeric purity 99%).

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(synthesis of perindopril from hexahydroindolecarboxylate and


bromopropionyl chloride)
RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L17 ANSWER 5 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1262577 HCAPLUS

DOCUMENT NUMBER: 144:7098

TITLE: Process for the preparation of perindopril and its salts

INVENTOR(S): Merslavic, Marjo; Smid, Janja; Tomsic, Zdenka

PATENT ASSIGNEE(S): Krka, Tovarna Zdravil D.D. Novo Mesto, Slovenia

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113500	A1	20051201	WO 2005-EP5048	20050510

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

SI 21800 C 20051231 SI 2004-143 20040514

SI 21852 C 20060228 SI 2004-235 20040805

PRIORITY APPLN. INFO.:

SI 2004-143 A 20040514

SI 2004-235 A 20040805

OTHER SOURCE(S): MARPAT 144:7098

AB The invention relates to a process for the preparation of the ACE inhibitor perindopril, its pharmaceutically-acceptable salts and intermediates obtained in the process. The process involves conversion of N-[(1S)-1-carbethoxybutyl]-L-alanine to the acid chloride hydrochloride and reaction with (2S,3aS,7aS)-octahydroindole-2-carboxylic acid or a an ester or salt. The examples describe the synthesis of perindopril erbumine by reactions carried out in CH₂Cl₂.

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for preparation of perindopril and its salts)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1201076 HCAPLUS

DOCUMENT NUMBER: 143:446810

TITLE: Processes for the preparation of alpha polymorph of perindopril erbumine

INVENTOR(S): Joshi, Narendra Shriram; Bhirud, Shekhar Bhaskar; Rao, Kodali Eswara

PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Limited, India

SOURCE: U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005250706	A1	20051110	US 2005-122731	20050505
WO 2005108365	A1	20051117	WO 2005-IB1233	20050506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: IN 2004-MU531 A 20040507
US 2004-572402P P 20040519

OTHER SOURCE(S): MARPAT 143:446810

AB A process for the preparation of an alpha polymorph of perindopril erbumine is provided comprising (a) forming a solution comprising perindopril erbumine in one or more ketones; (b) heating the solution to reflux; and (c) cooling the solution to a temperature sufficient to form the alpha polymorph of perindopril erbumine. The alpha polymorphs of perindopril erbumine obtained herein have a high purity level.

IT 107133-36-8P, Perindopril erbumine

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (of perindopril erbumine α -polymorph)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 7 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1146100 HCAPLUS

DOCUMENT NUMBER: 143:420385

TITLE: Development of efficient genotyping method for detecting insertion/deletion type polymorphisms of human angiotensin converting enzyme gene

INVENTOR(S): Katsutani, Tomohiro; Sugimoto, Ken; Akasaka, Tadashi; Ogiwara, Toshio

PATENT ASSIGNEE(S): EBS K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005295938	A2	20051027	JP 2004-119417	20040414
PRIORITY APPLN. INFO.:			JP 2004-119417	20040414

AB An efficient genotyping method for detecting insertion/deletion type polymorphism of human angiotensin converting enzyme gene. The method is designed to detect the polymorphisms in the extracted genomic DNA samples by the real time PCR using the specifically designed primers and probes with

fluorometric (FRET) detection. The ACE gene polymorphism anal. is especially established for diagnostic prediction of the genetic susceptibility to cardiac infarction, cardiac hypertrophy, diabetic nephropathy, IgA nephropathy or purpura nephritis. The ACE genotypes are classified into the DD, ID and II types and the order of the susceptibility to the above mentioned diseases is DD > ID > II. The genotyping method is also applied to predict the effectiveness of the ACE inhibitors in the therapy of hypertension. The order of the effectiveness of the ACE inhibitors is DD > ID > II. The ACE inhibitors that can be subjected to this effectiveness prediction test are alacepril, imidapril hydrochloride, quinapril hydrochloride, temocapril hydrochloride, delapril hydrochloride, benazepril hydrochloride, captopril, trandolapril, perindopril erbumine, enalapril maleate, lisinopril, lactotripeptide and the peptides from dried bonito or sardine.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effectiveness dependent on genotype; development of efficient genotyping method for detecting insertion/deletion type polymorphisms of human angiotensin converting enzyme gene)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 8 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1117891 HCAPLUS
 DOCUMENT NUMBER: 143:367597
 TITLE: Process for the preparation of perindopril
 INVENTOR(S): Kankan, Rajendra Narayanrao; Rao, Dharmaraj
 Ramachandra
 PATENT ASSIGNEE(S): Neopharma Limited, UK
 SOURCE: Brit. UK Pat. Appl., 21 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2413128	A1	20051019	GB 2004-8258	20040413
WO 2005100317	A1	20051027	WO 2005-GB1355	20050407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2004-8258 A 20040413

OTHER SOURCE(S): MARPAT 143:367597

AB A process for preparing perindopril or a pharmaceutically-acceptable salt comprises coupling a 4-halo-, 4-alkoxy- or 4-nitrobenzyl ester of (2S,3aS,7aS)-2-carboxyoctahydroindole with N-[(S)-1-carbethoxybutyl]-L-alanine (1) in the presence of DCC and HOBT, followed by catalytic hydrolysis. The starting ester was obtained from (S)-indoline-2-carboxylic acid by hydrogenation-esterification and 1 was obtained from norvaline Et ester and pyruvic acid under catalytic hydrogenation conditions. The method was applied to the synthesis perindopril erbumine (20.5 g obtained from 24 g 4-chlorobenzyl ester and 21.26 g 1).

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of perindopril by acylation of octahydroindolecarboxylates with ethoxycarbonylbutylalanine)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ 117 ANSWER 9 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1103553 HCAPLUS

DOCUMENT NUMBER: 143:373364

TITLE: Process for preparing a solid pharmaceutical composition of perindopril

INVENTOR(S): Klobcar, Iztok; Puncuh-Kolar, Alesa; Grandovec, Anica; Turk, Urska; Solmajer-Lampic, Polona

PATENT ASSIGNEE(S): Krka, Tovarna Zdravil D.D. Novo Mesto, Slovenia

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005094793	A1	20051013	WO 2005-EP3277	20050329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004019845	A1	20051020	DE 2004-102004019845	20040329

PRIORITY APPLN. INFO.:

DE 2004-102004019845A 20040329

DE 2004-102004059521A 20041209

AB The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compns., like tablets. A composition also comprises indapamide. For example, tablets were prepared by compression of a dry mixture comprising perindopril erbumine 4 mg, indapamide 1.25 mg, microcryst. cellulose 22.50 mg, lactose monohydrate 71.03 mg, sodium bicarbonate 0.50 mg, colloidal silica 0.27 mg, and magnesium stearate 0.45 mg.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perindopril solid compns. comprising carbonate stabilizer)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:729537 HCAPLUS

DOCUMENT NUMBER: 143:211920

TITLE: Preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics.

INVENTOR(S): Ogawa, Nobuya; Okuma, Chihiro; Furukawa, Noboru
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan; Amgen Sf, Llc
 SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072740	A2	20050811	WO 2005-JP1643	20050128
WO 2005072740	A3	20051027		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

JP 2004-24812 A 20040130
 US 2004-598037P P 20040802

OTHER SOURCE(S): MARPAT 143:211920
 GI




I

- AB Claimed are anorectics comprising as active ingredients compds. having DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrugs or a pharmaceutically acceptable salts thereof. Thus, title compound (I) (preparation given) at 10 mg/kg orally in rats gave a 30% reduction in food consumption after 8 h.
- IT 107133-36-8, Perindopril erbumine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics)
- RN 107133-36-8 HCAPLUS
- CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)
- CM 1


CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



117 ANSWER 11 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:698368 HCAPLUS

DOCUMENT NUMBER: 143:173145

TITLE: Preparation of perindopril

INVENTOR(S): Bhirud, Shekhar Bhaskar; Ahmed, Suhail; Chandrasekhar, Batchu; Purushotham, Vandanapu Loka Appala

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005171165	A1	20050804	US 2004-985097	20041110
PRIORITY APPLN. INFO.:			IN 2003-MU1179	A 20031112
			US 2004-569041P	P 20040507
OTHER SOURCE(S):		CASREACT 143:173145		
GI:				



AB A process for preparing a novel intermediate, oxathiazolidinedione I, in the preparation of perindopril is provided. Thus, reacting thionyl chloride in CH₂Cl₂ with imidazole and N-1(S)-(carboxyethyl)butyl-(S)-alanine gave I. Also provided are improved processes for the preparation of perindopril erbumine comprising (a) reacting I with a silylated octahydroindole-1H-2-carboxylic acid II to form perindopril; and (b) reacting perindopril with tert-butylamine to form perindopril erbumine.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of perindopril and perindopril erbumine)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



✓
 L17 ANSWER 12 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:673315 HCAPLUS
 DOCUMENT NUMBER: 143:159626
 TITLE: Inclusion complexes of perindopril
 INVENTOR(S): Rucman, Rudolf
 PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068490	A1	20050728	WO 2005-EP282	20050113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

SI 21703 C. 20050831 SI 2004-11 20040114

PRIORITY APPLN. INFO.: SI 2004-11 A 20040114

AB Complexes of the ACE-inhibitor perindopril, a salt, an addition salt or a derivative thereof with cyclodextrins, polyvinylpyrrolidone or hydroxypropyl cellulose, and processes for their preparation are described. E.g., complexes of perindopril erbumine with β -cyclodextrin and Me and hydroxypropyl β -cyclodextrins were prepared

IT 107133-36-8DP, Perindopril erbumine, compds., with hydroxypropyl and Me cyclodextrins

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inclusion complexes of perindopril)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



IT 107133-36-8, Perindopril erbumine
 RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
 (Reactant or reagent); USES (Uses)
 (inclusion complexes of perindopril)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
 with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:673261 HCAPLUS
 DOCUMENT NUMBER: 143:153713
 TITLE: New crystalline form of perindopril
 INVENTOR(S): Rucman, Rudolf
 PATENT ASSIGNEE(S): Lek Pharmaceuticals D. D., Slovenia
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068425	A1	20050728	WO 2005-EP283	20050113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

SI 21704 C 20050831 SI 2004-12 20040114
 PRIORITY APPLN. INFO.: SI 2004-12 A 20040114
 OTHER SOURCE(S): CASREACT 143:153713

AB The invention relates to a process for the preparation of ACE inhibitor perindopril which starts from N-[(S)-1-carbethoxybutyl]-L-alanine and involves trimethylsilyl protection and conversion to reactive acid chloride for reaction with (2S,3aS,7aS)-octahydroindole-2-carboxylic acid having a protected carboxyl group. The invention also relates to new crystalline and amorphous forms of perindopril. Thus, perindopril obtained by reaction of silylated reactants was purified by filtering a CH₂Cl₂ solution through a silica gel column and crystallizing from an Et ether solution Perindopril in new crystalline form (78.2%) was obtained.

IT 107133-36-8P, Perindopril erbumine
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of perindopril in new crystalline form)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

117. ANSWER 14 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:371219 HCAPLUS

DOCUMENT NUMBER: 142:435775

TITLE: Novel method for preparation of crystalline perindopril erbumine

INVENTOR(S): Singh, Girij Pal; Godbole, Himanshu Madhav; Nehate, Sagar Purushottam

PATENT ASSIGNEE(S): Lupin Ltd., India

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037788	A1	20050428	WO 2003-IN340	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003300689

A1 20050505

AU 2003-300689


20031021

PRIORITY APPLN. INFO.:

WO 2003-IN340

A 20031021

GI



AB Crystalline perindopril erbumine (I.H₂NBu-tert) is prepared and the x-ray (powder) diffraction pattern given. The process comprises reacting a solution of perindopril (I), in a solvent selected from DMF or di-Me acetals of lower aliphatic aldehydes and ketones with tertiary butylamine and crystallization

of the erbumine salt thus obtained by heating the reaction mixture to reflux, filtering hot, cooling gradually to 20-30°, and further cooling to 0-15° for 30 min-1 h and finally filtering off and drying the crystals.

IT 107133-36-8P, Perindopril erbumine

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline perindopril erbumine)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI). (CA INDEX NAME)

CM 1


CRN 82834-16-0

CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 NREFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ 17 ANSWER 15 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:216790 HCAPLUS

DOCUMENT NUMBER: 142:298121

TITLE: Preparation of biphenyl or phenylheterocyclyl
moiety-containing esters as inhibitors of microsomal
triglyceride transfer proteinINVENTOR(S): Hagiwara, Atsushi; Ikenogami, Taku; Mera, Yasuko;
Sumida, Yukako; Iida, Akio; Taniguchi, Toshio;
Takahashi, Mitsuru

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021486	A1	20050310	WO 2004-JP12407	20040827
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2003-305877 A 20030829

OTHER SOURCE(S): MARPAT 142:298121

GI



AB The title compds. I [R1, R2 = H, alkyl, etc.; ring A = aryl, etc.; X = CO2(CH2)n, etc.; n = 0 - 3; R3, R4, R200 = H, halo, etc.; ring B = phenylene, etc.; ring C = Ph, etc.; R5, R6, R7 = H, alkyl, etc.; R8, R9 = H, (un)substituted alkyl, etc.; E = O, etc.; Y = OCO, etc.; Alk1, Alk2 = alkanediyl, etc.; 1, m = 0 - 3] are prepared Thus, di-Et 2-(2-[3-acetoxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl]acetoxymethyl)-2-phenylmalonate was prepared in 2 steps from di-Et 2-(2-[3-benzyloxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl]acetoxymethyl)-2-phenylmalonate. In a test for the inhibition of triglyceride transfer activity between liposomes by microsomal triglyceride transfer protein, compds. of this invention showed IC50 values of < 10 nM to 1000 nM. Formulations are given.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination of biphenyl or phenylheterocyclyl moiety-containing esters (as inhibitors of microsomal triglyceride transfer protein) and α - and β -blockers)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0


CMF C19 H32 N2 O5

Absolute stereochemistry: Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ E17 ANSWER 16 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:182626 HCAPLUS

DOCUMENT NUMBER: 142:280052

TITLE: Process for pure perindopril tert-butylamine salt

INVENTOR(S): Parthasaradhi Reddy, Bandi; Rathnakar Reddy, Kura; Raji Reddy, Rapolu; Muralidhara Reddy, Dasari; Ramakrishna Reddy, Matta

PATENT ASSIGNEE(S): Hetero Drugs Limited, India

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019173	A1	20050303	WO 2003-IN276	20030821
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003263584	A1	20050310	AU 2003-263584	20030821
PRIORITY APPLN. INFO.: GI			WO 2003-IN276	A 20030821



AB Pure perindopril tert-butylamine salt is obtained by extracting an aqueous solution of perindopril (I), namely (2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-

(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, or its salt contaminated with impurities with a suitable organic solvent such as methylene dichloride at a pH of 4.0 to 6.5, separating the organic layer, isolating I from the organic layer and converting it into tert-butylamine salt. Thus, perindopril tert-butylamine salt (15 g, purity 92.4%) was added to water (100 mL) and CH₂Cl₂ (100 mL) and the pH of the mass was adjusted to 5.4 by using 20% dilute HCl. The phases were separated and the aqueous layer was washed with CH₂Cl₂ (2 x 75 mL). The CH₂Cl₂ layer and washings are combined and the combined organic phase was washed with water (50 mL) and then with 10% aqueous NaCl (50 mL). The organic layer

was

dried over Na₂SO₄ and concentrated to give a residue, perindopril, (99.3 % purity). EtOAc (255 mL) was added to the residue (15 g) and stirred for 10 min to obtain a clear solution. Tert-Butylamine was added dropwise to the solution at 30° and stirred for 1 h at the same temperature. The reaction mass was then heated to reflux, passed over hiflo rapidly at reflux temperature and washed with hot EtOAc (30 mL). Then, the reaction mass was stirred for 2 h at approx. 30°, cooled to 0°, and stirred for further 2 h at 0° to 5°. The separated solid was filtered, washed with EtOAc (15 mL), and dried to give 12 g of 99.77% pure perindopril tert-butylamine salt.

IT 107133-36-8P, Perindopril tert-butylamine salt

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for pure perindopril tert-butylamine salt)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 17 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:99521 HCAPLUS

DOCUMENT NUMBER: 142:156329

TITLE: Preparation of α -amino acid benzothiazolylthio esters as intermediates for manufacture of ACE inhibitors

INVENTOR(S): Singh, Girij Pal; Godbole, Himanshu Madhav; Mahajan, Pravin Raghunath; Nehate, Sagar Purushottam

PATENT ASSIGNEE(S): Lupin Limited, India

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005010028	A1	20050203	WO 2003-IN257	20030731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003272077	A1	20050214	AU 2003-272077	20030731
PRIORITY APPLN. INFO.:			WO 2003-IN257	A 20030731

OTHER SOURCE(S): CASREACT 142:156329; MARPAT 142:156329

AB The invention relates to esters (S,S)-RCH₂CH₂CH(CO₂R₁)NHCHR₂CO-X (I; R is alkyl or Ph; R₁ H or alkyl; R₂ is alkyl or aminoalkyl; X is 2-benzothiazolylthio) which are intermediates in the manufacture of ACE inhibitors I (X is an amino acid or derivative). The intermediate benzothiazolylthio esters were prepared by reaction of the appropriate acid or acid chloride with 2,2'-dithiobis(benzthiazole) or 2-mercaptobenzothiazole. Thus, treatment of N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-N₆-(trifluoroacetyl)-L-lysine (preparation given) with 2,2'-dithiobis(benzothiazole), followed by coupling with L-proline Et ester and deprotection, afforded lisinopril dihydrate.

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of α -amino acid benzothiazolylthio esters as intermediates for manufacture of ACE inhibitors)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 18 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:99360 HCAPLUS

DOCUMENT NUMBER: 142:170093

TITLE: Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome

INVENTOR(S): Fong, Benson M.; Cornett, Glen V.

PATENT ASSIGNEE(S): Cotherix, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009446	A1	20050203	WO 2004-US23004	20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2532807 AA 20050203 CA 2004-2532807 20040716
 US 2005043391 A1 20050224 US 2004-892601 20040716
 PRIORITY APPLN. INFO.: US 2003-488040P P 20030717
 WO 2004-US23004 W 20040716

AB Preferred embodiments of the invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.

IT 107133-36-8, Coversyl

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

117 ANSWER 19 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 V ACCESSION NUMBER: 2004:1154670 HCAPLUS
 DOCUMENT NUMBER: 142:62765
 TITLE: Preparation of various crystalline forms of perindopril erbumine for use as drug
 INVENTOR(S): Straessler, Christoph; Lellek, Vit; Faessler, Roger
 PATENT ASSIGNEE(S): Azad Pharmaceutical Ingredients AG, Switz..
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113293	A1	20041229	WO 2004-CH374	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2530550	AA	20041208	CA 2004-2530550	20040618
AU 2004249345	A1	20041229	AU 2004-249345	20040618
EP 1636185	A1	20060322	EP 2004-737029	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			CH 2003-1109	A 20030624
			WO 2004-CH374	W 20040618
AB Disclosed are two novel crystalline forms d and e of perindopril erbumine, which are suitable as therapeutic substances in medicaments used for treating cardiovascular diseases, especially high blood pressure and cardiac insufficiency. Crystalline form e is obtained by crystallizing perindopril erbumine from MTBE containing 1.5 to 2.5 % (volume/volume) of water at 30 to 45°, preferably 34 to 45°, crystallization expediently taking place by stirring. Crystalline form e changes into crystalline form d if the water is removed, practically by azeotropic distillation, preferably at 35 to 37°, and stirring continues for at least 15 h at 30 to 45°, preferably 35 to 37°. Crystalline form d can also be obtained by stirring crystalline form a or ss in tert-Bu Me ether containing 0.9 to 1.4 % (volume/volume) of water at				
33 to 38° while inoculating the same with crystalline form d. Crystalline form				

e can further be obtained by stirring crystalline form a or ss in tert-Bu Me ether containing 0.9 to 1.4 % (volume/volume) of water at 28 to 35° while inoculating the same with crystalline form e, or by stirring crystalline form a or

ss in tert-Bu Me ether containing 1.5 to 2.0 % (volume/volume) of water at 35 to 38°.

IT 107133-36-8, Perindopril erbumine

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(preparation of various crystalline forms of perindopril erbumine for use as drug)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 20 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1106652 HCAPLUS

DOCUMENT NUMBER: 142:68777

TITLE: Clinicopathological factors that affect the therapeutic benefits of inhibitors of the renin

AUTHOR(S): angiotensin system in patients with IgA nephropathy
 Moriyama, Takahito; Nitta, Kosaku; Uchida, Keiko;
 Yumura, Wako; Nihei, Hiroshi
 CORPORATE SOURCE: Department of Medicine IV, Tokyo Women's University
 School of Medicine, Tokyo, 162-8666, Japan
 SOURCE: Tokyo Joshi Ika Daigaku Zasshi (2004), 74(11), 632-641
 CODEN: TJIZAF; ISSN: 0040-9022
 PUBLISHER: Tokyo Joshi Ika Daigaku Gakkai
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Recent studies have shown that inhibitors of the renin-angiotensin system (I-RAS) such as angiotensin converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) are effective for IgA nephropathy (IgAN). However, the precise mechanism of the effects remains unknown. The present study was conducted to elucidate the pathol. factors affecting the therapeutic benefits of I-RAS in IgAN. Twenty-six IgAN patients were studied retrospectively. The patients were divided into two groups according to the grade of reduction of urinary protein excretion: the responder group (n = 12) and the non-responder group (n = 14). The modality of treatment was determined by the clin. and histol. findings of each patient. No significant difference before treatment was observed between the responder and non-responder groups. In the evaluation of the outcome after treatment, the amts. of urinary protein excretion one year after treatment and at the final observation significantly decreased in the responder group but remained unchanged in the non-responder group. However, the levels of serum-creatinine, urinary red blood cell sediment, and mean blood pressure were not significantly different between both groups. Histol., the rate of glomerular obsolescence, interstitial inflammatory cell infiltration and interstitial fibrosis tended to be higher in the non-responder group than in the responder group, and the rate of crescent formation tended to be higher in the responder group than in the non-responder group, but did not reach statistical significance. The grades of mesangial cell proliferation and mesangial matrix increase were not significantly different between both groups. The grade of arterio- and arteriolosclerosis was significantly higher in the non-responder group than in the responder group (0.92 ± 0.52 vs. 1.91 ± 1.08 , $p = 0.043$, 1.08 ± 0.79 vs. 1.78 ± 0.97 , $p = 0.033$). These findings suggest that arterio- and arteriolo-sclerosis could be a predictor for the effectiveness of I-RAS in IgAN patients.


IT 107133-36-8, Perindopril erbumine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (clinicopathol. factors including arteriosclerosis that affect therapeutic benefits of inhibitors of renin angiotensin system in patients with IgA nephropathy)
 RN 107133-36-8 HCAPLUS
 CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0


CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



✓ L17 ANSWER 21 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1058387 HCAPLUS

DOCUMENT NUMBER: 142:28182

TITLE: Stabilized solid compositions containing bioactive components and silicate salts, and manufacture thereof

INVENTOR(S): Matsumoto, Takahiro

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004346066	A2	20041209	JP 2004-132348	20040428

PRIORITY APPLN. INFO.: JP 2003-125945 A 20030430

AB The invention relates to a pharmaceutical solid composition having improved stability against high-temperature and high-humidity, wherein the composition is characterized by containing a bioactive component, especially an ACE inhibitor, and

a silicic acid salt. A tablet containing perindopril erbumine 2, calcium silicate (CaSiO₃) 5, anhydrous lactose 102.25, silica 0.2, and magnesium stearate 0.55 mg was formulated.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stabilized solid compns. containing bioactive components and silicate salts, and manufacture thereof)

RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.


with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 22 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:996205 HCAPLUS

DOCUMENT NUMBER: 141:395815

TITLE: A process for the preparation of perindopril using tetramethyluronium salts as coupling reagents

INVENTOR(S): Rucman, Rudolf

PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099236	A1	20041118	WO 2004-SI20	20040507
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

SI 21506 C 20041231 SI 2003-118 20030508
 EP 1628995 A1 20060301 EP 2004-731809 20040507

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:

SI 2003-118 A 20030508
 WO 2004-SI20 W 20040507

OTHER SOURCE(S): CASREACT 141:395815; MARPAT 141:395815

AB A process for the preparation of the ACE inhibitor perindopril involves activation of N-[1(S)-(ethoxycarbonyl)butyl]-(S)-alanine (1) with a tetramethyluronium salt in the presence of a tertiary organic base, coupling with (2S,3aS,7aS)-octahydroindole-2-carboxylic acid (2) or an ester, and deprotection. Thus, a mixture of 1, 2 benzyl ester, TBTU and diisopropylethylamine in DMF/CH₂Cl₂ was stirred for 4 h to afford benzyl-perindopril, which was converted to perindopril by phase transfer or classical hydrogenation.

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of perindopril using tetramethyluronium salts as coupling reagents)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L17 ANSWER 23 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:996123 HCAPLUS
 DOCUMENT NUMBER: 141:411226
 TITLE: Process for preparation of perindopril and its salts
 INVENTOR(S): Kankan, Rajendra Narayanrao; Rao, Dharmaraj
 Ramachandra
 PATENT ASSIGNEE(S): Cipla Limited, India; Wain, Christopher Paul
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099138	A2	20041118	WO 2004-GB2029	20040512
WO 2004099138	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2003-MU468 A 20030512
 OTHER SOURCE(S): CASREACT 141:411226; MARPAT 141:411226

AB A process for preparing perindopril or a pharmaceutically-acceptable salt comprises esterifying (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid (I) with benzyl alc. (or the 4-chloro or 4-alkoxy derivative) in the presence of benzenesulfonic acid as catalyst, treating the intermediate ester benzenesulfonate with N-[(S)-1-carbethoxybutyl]-L-alanine (II), and ester cleavage. Thus, I benzyl ester benzenesulfonate (40 g) was prepared, its suspension in CH₂Cl₂ made alkaline with aqueous ammonia, and the organic layer separated

Treatment with II at 10-15 °C in the presence of hydroxybenzotriazole and N,N'-dicyclohexylcarbodiimide and workup afforded 43 g perindopril benzyl ester.

IT 107133-36-8P, Perindopril erbumine
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of perindopril and its salts)

RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.


with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 24 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:930759 HCAPLUS

DOCUMENT NUMBER: 142:254148

TITLE: Efficiency of Refracterin in Patients with Chronic Cardiac Insufficiency Caused by Coronary Heart Disease
AUTHOR(S): Kanorskii, S. G.; Galenko-Yaroshevskii, P. A.; Zingilevskii, K. B.

CORPORATE SOURCE: Krasnodar Research Center, Russian Academy of Medical Sciences, Russia

SOURCE: Bulletin of Experimental Biology and Medicine (Translation of Byulleten Eksperimental'noi Biologii i Meditsiny) (2004), 138(1), 67-69
CODEN: BEXBAN; ISSN: 0007-4888

PUBLISHER: Springer Science+Business Media, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Composite preparation refracterin administered in a dose of 300 mg/day for 3 days in addition to routine therapy significantly improved the results of treatment of severe cardiac insufficiency of ischemic genesis compared to placebo. Improvement of clin. status of patients is determined by pos. dynamics of systolic and diastolic functions of the left ventricle.

IT 107133-36-8, Prestarium

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(short term refracterin therapy efficiently improved result of routine treatment involving perindopril by induction of pos. change in systolic and diastolic function of LV in patient with chronic cardiac insufficiency caused by CHD)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 25 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:902177 HCAPLUS

DOCUMENT NUMBER: 141:374721

TITLE: Use of an ACE inhibitor or angiotensin II receptor antagonist for decreasing the incidence of atrial fibrillation in patients with left ventricular dysfunction

INVENTOR(S): Ducharme, Anique; Tardif, Jean-Claude; Bourassa, Martial-G.

PATENT ASSIGNEE(S): Institut de Cardiologie de Montreal / Montreal Heart Institute, Can.

SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091608	A1	20041028	WO 2004-CA568	20040415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2517707	AA	20041028	CA 2004-2517707	20040415
EP 1613306	A1	20060111	EP 2004-727489	20040415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			US 2003-462734P	P 20030415
			WO 2004-CA568	W 20040415

AB Atrial fibrillation (AF) is frequently encountered in patients with heart failure (HF) and is also a predictor of morbidity and mortality in this population. Recent exptl. studies have shown elec. and structural atrial remodeling with increased fibrosis in HF animals, and have suggested a preventive effect of angiotensin converting enzyme inhibitors (ACEi) on the development of AF. To verify the hypothesis that ACEi prevent the development of AF in patients with HF, a retrospective anal. of the patients from the Montreal Heart Institute included in the Studies Of Left Ventricular Dysfunction was conducted. The results of this retroactive anal. indicate that treatment with the ACE inhibitor, e.g. enalapril, can markedly reduce the risk of developing atrial fibrillation in patients with left ventricular dysfunction.

IT 107133-36-8, Coversyl
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ACE inhibitor or angiotensin II receptor antagonist for decreasing incidence of atrial fibrillation in patient with left ventricular dysfunction)


RN 107133-36-8 HCAPLUS
 CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 26 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:759824 HCAPLUS

DOCUMENT NUMBER: 141:254560

TITLE: Composition and method using a leukotriene inhibitor, an antihistamine and a corticosteroid for treating inflammation by reducing C-reactive protein

INVENTOR(S): Mullally, John P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004180868	A1	20040916	US 2004-798117	20040311
CA 2518409	AA	20040923	CA 2004-2518409	20040311
WO 2004080414	A2	20040923	WO 2004-US7381	20040311
WO 2004080414	A3	20050512		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

PRIORITY APPLN. INFO.:

US 2003-453917P P 20030312
US 2003-482574P P 20030624
WO 2004-US7381 W 20040311

AB A method and composition for reducing C-reactive protein for reducing systemic inflammation in the body of a user is achieved through the daily administration of a leukotriene inhibitor, an antihistamine, and a corticosteroid. The composition may be administered singly or as a single medicament. Typically, the leukotriene inhibitor and antihistamine are administered orally.

IT 107133-36-8, Aceon

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(leukotriene inhibitor, antihistamine, and corticosteroid for treating inflammation by reducing C-reactive protein)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 27 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648315 HCAPLUS

DOCUMENT NUMBER: 141:179622

TITLE: Controlled release pharmaceutical compositions

containing polymers
 INVENTOR(S): Kannan, Muthaiyyan Esakki; Krishnan, Anandi; Sapre, Beena Amol; Shah, Chitra; Patil, Atul
 PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Ltd., India
 SOURCE: PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004066910	A2	20040812	WO 2004-IB274	20040126
WO 2004066910	C1	20041007		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004185097	A1	20040923	US 2004-762180	20040121
CA 2493899	AA	20040812	CA 2004-2493899	20040126
EP 1599190	A2	20051130	EP 2004-705137	20040126
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			IN 2003-MU132	A 20030131
			US 2003-517589P	P 20031105
			IN 2003-MU130	A 20030131
			WO 2004-IB274	W 20040126

AB A solid controlled release pharmaceutical composition suitable comprises a drug, a primary release-modifying agent, a secondary release-modifying agent and an auxiliary release-modifying agent, which are present in amts. that synergistically extend the release of the active ingredient. Thus, tablets contained nicotinic acid 500.00, PEG (mol. weight 4,000,000) 170.0, retrograde starch 40.00, lactose monohydrate 30.00, talc 5.00, and Mg stearate 5.00 mg, and water qs.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled release pharmaceutical compns. containing polymers)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 28 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:552033 HCAPLUS

DOCUMENT NUMBER: 141:179795

TITLE: Enantioselective, potentiometric membrane electrode, based on vancomycin as chiral selector, for the assay of S-perindopril

AUTHOR(S): Ozoemena, Kenneth I.; Stefan, Raluca-Ioana; van Staden, Jacobus F.; Aboul-Enein, Hassan Y.

CORPORATE SOURCE: Department of Chemistry, University of Pretoria, Pretoria, S. Afr.

SOURCE: Instrumentation Science & Technology (2004), 32(4), 371-378

CODEN: ISCTEF; ISSN: 1073-9149

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The construction of an enantioselective, potentiometric membrane electrode (EPME) based on carbon paste impregnated with macrocyclic antibiotic vancomycin (VCM) as chiral selector is described. The proposed electrode was applied for the assay of S-perindopril (S-Pdp) raw material and from its pharmaceutical formulation (Coversyl tablets) by use of a direct potentiometric method. The surfaces of the electrode can easily be renewed by simply polishing on an alumina paper.

IT 107133-36-8, Coversyl

RL: ANT (Analyte); ANST (Analytical study)

(enantioselective, potentiometric membrane electrode, based on vancomycin as chiral selector, for the assay of S-perindopril)


RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 29 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:427629 HCAPLUS

DOCUMENT NUMBER: 140:407114

TITLE: Method for synthesis of perindopril and its pharmaceutically-acceptable salts

INVENTOR(S): Dubuffet, Thierry; Langlois, Pascal

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1422236	A1	20040526	EP 2003-292865	20031119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005054277	A1	20050616	WO 2004-FR2937	20041118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

PRIORITY APPLN. INFO.:

EP 2003-292865

A 20031119

OTHER SOURCE(S):

MARPAT 140:407114

AB Perindopril was prepared by cyclization of (2S)-3-(2-bromophenyl)-2-[[[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]propanoyl]amino]propanoic acid (I) or its esters in the presence of a Pd-based catalyst and a base [e.g., Pd₂(dba)₃, P(o-tolyl)₃, and Cs₂CO₃], followed by catalytic hydrogenation. Intermediate I was prepared by coupling of N-[(S)-1-carbethoxybutyl]-L-alanine N-carboxyanhydride with (S)-2-bromophenylalanine.

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(synthesis of perindopril and its pharmaceutically-acceptable salts)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 30 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:405692 HCAPLUS

DOCUMENT NUMBER: 140:407109

TITLE: Hydrogenolysis of benzyl ester of perindopril for preparing perindopril monohydrates for use as inhibitors of angiotensin converting enzyme (ACE)

INVENTOR(S): Rao, Dharmaraj Ramachandra; Kankan, Rajendra Narayanrao

PATENT ASSIGNEE(S): Cipla Limited, India

SOURCE: Brit. UK Pat. Appl., 16 pp.

CODEN: BAXXDU



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2395195	A1	20040519	GB 2002-26885	20021118
CA 2506587	AA	20040603	CA 2003-2506587	20031118
WO 2004046172	A1	20040603	WO 2003-GB4981	20031118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003283588	A1	20040615	AU 2003-283588	20031118
EP 1565485	A1	20050824	EP 2003-775565	20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015703	A	20051025	BR 2003-15703	20031118
CN 1738830	A	20060222	CN 2003-80108700	20031118
US 2006063941	A1	20060323	US 2005-535187	20051031
PRIORITY APPLN. INFO.:			GB 2002-26885	A 20021118
			WO 2003-GB4981	W 20031118
OTHER SOURCE(S):			CASREACT 140:407109; MARPAT 140:407109	
GI				



AB Perindopril (I), or a pharmaceutically acceptable salt thereof, may be prepared from a protected ester II (R = aralkyl, CH₂Ph) via hydrogenolysis in the presence of a noble metal catalyst, such as Pd/charcoal, in the presence of a base. For example, when the base is tert-butylamine, it forms a pharmaceutically-acceptable addition salt with I, thus forming perindopril erbumine, I·tert-butylamine salt. A monohydrate of I, or a pharmaceutically acceptable salt thereof, is also claimed and may be prepared by hydrating I, or a pharmaceutically acceptable salt thereof, by way of addition of water or by drying in air. Perindopril erbumine monohydrate was prepared and studied by x-ray diffraction. Perindopril monohydrates may be used as angiotensin converting enzyme (ACE) inhibitors.

IT 107133-36-8P, Perindopril erbumine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of perindopril, its salts and monohydrates from hydrogenolysis of its benzyl ester)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 31 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:405663 HCAPLUS
 DOCUMENT NUMBER: 140:375491
 TITLE: Method for the synthesis of perindopril and its pharmaceutically-acceptable salts
 INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre
 PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
 SOURCE: Eur. Pat. Appl., 6 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1420029	A2	20040519	EP 2003-293084	20031210
EP 1420029	A3	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005066198	A1	20050721	WO 2004-FR3166	20041209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-293084 A 20031210
 AB A method for the synthesis of perindopril involves coupling of (2S)-indoline-2-carboxylic acid benzyl ester or (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester with N-[(S)-1-carbethoxybutyl]-L-alanine in the presence of a coupling agent [e.g., O-(benzotriazol-1-yl)-1,1,3,3-bis(tetramethylene)uronium hexafluorophosphate], followed by hydrogenation over Pd. Perindopril was converted into its tert-butylamine salt.
 IT 107133-36-8P, Perindopril erbumine
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of perindopril and its pharmaceutically-acceptable salts)
 RN 107133-36-8 HCAPLUS
 CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 82834-16-0
 CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 32 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:405662 HCAPLUS

DOCUMENT NUMBER: 140:375490

TITLE: Method for the synthesis of perindopril and its pharmaceutically-acceptable salts

INVENTOR(S): Dubuffet, Thierry; Langlois, Pascal

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1420028	A2	20040519	EP 2003-292864	20031119
EP 1420028	A3	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005054276	A1	20050616	WO 2004-FR2936	20041118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:


EP 2003-292864

A 20031119

OTHER SOURCE(S):

MARPAT 140:375490

GI



AB A method for the synthesis of perindopril involves reaction of indolinecarboxylate derivs. I (R = H or a protective group, G = Cl, Br, OH, TsO, MeSO₃ or CF₃SO₃) with (S)-PrCH(NH₂)CO₂Et (II), followed by catalytic hydrogenation. II was prepared by reaction of (S)-2-BrC₆H₄CH₂CH(NH₂)CO₂R with (R)-MeCH(G)COCl and intamol. coupling, e.g., in the presence of Pd₂(dba)₃, P(o-tolyl)₃, and Cs₂CO₃. Perindopril was converted into its tert-butylamine salt.

IT 107133-36-8P.

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of perindopril and its pharmaceutically-acceptable salts)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 33 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:363685 HCAPLUS

DOCUMENT NUMBER: 140:380637

TITLE: Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, e.g. silicon dioxide

INVENTOR(S): Bergman, Jeffrey; Mantri, Pranita S.

PATENT ASSIGNEE(S): Niche Generics Limited, UK; Unichem Laboratories Limited

SOURCE: Brit. UK Pat. Appl., 50 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2394660	A1	20040505	GB 2003-29232	20031217
PRIORITY APPLN. INFO.:			GB 2003-29232	20031217

OTHER SOURCE(S): MARPAT 140:380637

AB The present invention relates to stable pharmaceutical compns. comprising an ACE inhibitor (which are otherwise susceptible to degradation due to cyclisation, hydrolysis and oxidation). This is achieved by providing compns. substantially free of any acidic excipients having a large sp. surface area, especially substantially free of colloidal silicon dioxide. The composition also comprises one or more excipients, which are preferably compatible with the ACE inhibitor. The ACE inhibitor is preferably perindopril or ramipril. The composition may be used as a medicament for the treatment or prevention of a cardiovascular disorder, hypertension, coronary heart disease or a cerebrovascular disease. The composition may further comprise a β -blocker, a diuretic, a calcium-channel blocker, a vasodilator anti-hypertensive drug, or an angiotensin II receptor antagonist.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stabilization of pharmaceutical compns. comprising ACE inhibitor by absence of acidic excipients having large sp. surface area like silicon dioxide)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 34 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:351638 HCAPLUS

DOCUMENT NUMBER: 140:350628

TITLE: Prophylactic and therapeutic agents for treatment of fibrosis-associated chronic kidney disorders

INVENTOR(S): Nakagawa, Tsutomu; Nagamine, Jun

PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004131444	A2	20040430	JP 2002-298927	20021011
PRIORITY APPLN. INFO.:			JP 2002-298927	20021011
OTHER SOURCE(S):		MARPAT 140:350628		

GI



AB Title agents, which are used in combination with kidney-protecting pharmaceuticals, contain fibrosis inhibitors as active ingredients, or vice-versa. Thus, pyrrole derivative I (TGF- β inhibitor) and losartan showed synergistic efficacy in diabetic nephropathy in C57BL/KsJ-db/db mice.

IT 107133-36-8, Perindopril erbumine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (synergistic drugs containing kidney-protecting agents and fibrosis inhibitors for treatment of fibrosis-associated chronic kidney disorders)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 35 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:266897 HCAPLUS

DOCUMENT NUMBER: 140:253917

TITLE: Process for the synthesis of perindopril and its pharmaceutically-acceptable salts

INVENTOR(S): Dubuffet, Thierry; Langlois, Pascal

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1403275	A1	20040331	EP 2003-290485	20030228
EP 1403275	B1	20051019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 307139	E	20051115	AT 2003-290485	20030228
AU 2004217599	A1	20040916	AU 2004-217599	20040227
WO 2004078107	A2	20040916	WO 2004-FR446	20040227
WO 2004078107	A3	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-290485 A 20030228
WO 2004-FR446 A 20040227

OTHER SOURCE(S): MARPAT 140:253917

AB A method for the synthesis of perindopril involves coupling of (2S)-2,3,4,5,6,7-hexahydro-1H-indolecarboxylic acid (I) or an ester with N-[(S)-1-carbethoxybutyl]-L-alanine, followed by catalytic hydrogenation. I benzyl ester tosylate was prepared by reaction of 1-(1-cyclohexen-1-yl)pyrrolidine with (R)-ICH₂CH(NBoc)CO₂CH₂Ph (Boc = tert-butoxycarbonyl), followed by deprotection and cyclization. Perindopril was converted into its tert-butylamine salt.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(synthesis of perindopril and pharmaceutically-acceptable salts)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 36 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:203796 HCAPLUS

DOCUMENT NUMBER: 140:253571

TITLE: Preparation of N-phenyl or N-heterocyclyldibenzylamine compounds as inhibitors of cholesteryl ester transfer protein (CETP) and medicinal use thereof

INVENTOR(S): Maeda, Kimiya; Nagamori, Hironobu; Nakamura, Hiroshi; Shinkai, Hisashi; Suzuki, Yasunori; Takahashi, Daisuke; Taniguchi, Toshio

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 207 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020393	A1	20040311	WO 2003-JP11041	20030829
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

CA 2464846	AA	20040311	CA 2003-2464846	20030829
AU 2003261826	A1	20040319	AU 2003-261826	20030829
BR 2003006208	A	20041013	BR 2003-6208	20030829
JP 2004323504	A2	20041118	JP 2003-308156	20030829
JP 3630676	B2	20050316		
CN 1617850	A	20050518	CN 2003-802383	20030829
EP 1533292	A1	20050525	EP 2003-791414	20030829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
TR 200401413	T1	20050621	TR 2004-200401413	20030829
ZA 2004003137	A	20050425	ZA 2004-3137	20040423
NO 2004002584	A	20040618	NO 2004-2584	20040618
US 2005059810	A1	20050317	US 2004-503185	20041012
PRIORITY APPLN. INFO.:				A 20020830
				JP 2003-107161 A 20030410
				WO 2003-JP11041 W 20030829


OTHER SOURCE(S): MARPAT 140:253571
GI




AB Dibenzylamine compds. represented by the general formula (I) [R1, R2 = halo, NO2, cyano, C1-6 alkyl, halo-C1-6 alkyl; R3, R4, R5 = H, halo, each optionally halo-substituted C1-6 alkyl, C1-6 alkylthio, or C1-6 alkoxy; or R3 and R4 or R4 and R5 together with the carbon atoms bonded thereto form an (un)substituted halo- or heterocyclic ring; A = NR7R8; wherein R7, R8 = H, each (un)substituted C1-6 alkyl or C4-10 cycloalkyl, etc.; the ring B = aryl or heterocyclyl; R6 = H, halo, NO2, NH2, HO, cyano, acyl, C1-6 alkoxy, (un)substituted C2-6 alkenyl; n = an integer of 1-3] or prodrugs thereof or pharmaceutically acceptable salts thereof are prepared. These compds. have selective and potent CETP inhibitory activity, which results in lowering intermediate-d. lipoprotein (IDL), very low d. lipoprotein (VLDL), and low d. lipoprotein (LDL) which promote arteriosclerosis, and increasing high d. lipoprotein (HDL), and are hence usable as, e.g., therapeutic or preventive drugs for hyperlipemia and arteriosclerosis. Thus, 17 mg NaH was added to a solution of 132 mg N-[3-(N-cyclopentylmethyl-N-ethylamino)-5,6,7,8-tetrahydronaphthalen-2-ylmethyl]-(2-methyl-2H-tetrazol-5-yl)amine in 2 mL DMF, followed by adding 114 mg 3-bromomethyl-5-trifluoromethylbenzonitrile, and the resulting mixture was stirred at room temperature overnight to give, after workup and silica gel chromatog., 44% 3-[[N-[3-(N-cyclopentylmethyl-N-ethylamino)-5,6,7,8-tetrahydronaphthalen-2-ylmethyl]-N-(2-methyl-2H-tetrazol-5-yl)amino]methyl]-5-trifluoromethylbenzonitrile (II). II in vitro inhibited the activity of CETP in whole blood plasma with IC50 of 0.08 μ M.

IT 107133-36-8, Perindopril erbumine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antihypertensive, combination therapy; preparation of N-Ph or
 N-heterocyclidibenzylamine compds. as inhibitors of cholesteryl ester
 transfer protein (CETP) for treatment or prevention of hyperlipemia and
 arteriosclerosis)
 RN 107133-36-8 HCAPLUS
 CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-
 (ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
 with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 82834-16-0
 CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2
 CRN 75-64-9
 CMF C4 H11 N



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 37 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:145230 HCAPLUS

DOCUMENT NUMBER: 141:218619

TITLE: Rationale and design of a large-scale trial using
 nicorandil as an adjunct to percutaneous coronary
 intervention for ST-segment elevation acute myocardial
 infarction: Japan-working groups of acute myocardial
 infarction for the reduction of necrotic damage by a
 K-ATP channel opener (J-WIND-KATP)

AUTHOR(S): Minamino, Tetsuo; Kim, Jiyoong; Asakura, Masanori;
 Shintani, Yasunori; Asanuma, Hiroshi; Kitakaze,
 Masafumi

CORPORATE SOURCE: J-WIND Investigators, Japan Foundation for Aging and Health for Medical Frontier Strategy Research by Health and Labor Sciences Research Grants, National Cardiovascular Center, Suita, Japan

SOURCE: Circulation Journal (2004), 68(2), 101-106
CODEN: CJIOBY; ISSN: 1346-9843

PUBLISHER: Japanese Circulation Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: The benefits of percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are limited by reperfusion injury. In animal models, nicorandil, a hybrid of an ATP-sensitive K⁺ (KATP) channel opener and nitrates, reduces infarct size, so the Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP) designed a prospective, randomized, multicenter study to evaluate whether nicorandil reduces myocardial infarct size and improves regional wall motion when used as an adjunctive therapy for AMI. Methods and Results: Twenty-six hospitals in Japan are participating in the J-WIND-KATP study. Patients with AMI who are candidates for PCI are randomly allocated to receive either i.v. nicorandil or placebo. The primary end-points are (1) estimated infarct size and (2) left ventricular function. Single nucleotide polymorphisms (SNPs) that may be associated with the function of KATP-channel and the susceptibility of AMI to the drug will be examined. Furthermore, a data mining method will be used to design the optimal combined therapy for post-myocardial infarction (MI) patients. Conclusions: It is intended that J-WIND-KATP will provide important data on the effects of nicorandil as an adjunct to PCI for AMI and that the SNPs information that will open the field of tailor-made therapy. The optimal therapeutic drug combination will also be determined for post-MI patients.

IT 107133-36-8, Perindopril erbumine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nicorandil and cardiovascular agent for decreasing risk of cardiac events in patients with post-myocardial infarction)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 38 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:145229 HCAPLUS

DOCUMENT NUMBER: 141:219275

TITLE: Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-working groups of acute myocardial infarction for the reduction of necrotic damage by ANP (J-WIND-ANP)

AUTHOR(S): Asakura, Masanori; Kim, Jiyoong; Minamino, Tetsuo; Shintani, Yasunori; Asanuma, Hiroshi; Kitakaze, Masafumi

CORPORATE SOURCE: J-WIND Investigators, Japan Society for the Promotion of Science for Young Scientists, Osaka University Graduate School of Medicine, Suita, Japan

SOURCE: Circulation Journal (2004), 68(2), 95-100

CODEN: CJIOBY; ISSN: 1346-9843

PUBLISHER: Japanese Circulation Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: The benefits of percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are limited by reperfusion injury. In animal models, atrial natriuretic peptide (ANP) reduces infarct size, so the Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP) designed a prospective, randomized, multicenter study, to evaluate whether ANP as an adjunctive therapy for AMI reduces myocardial infarct size and improves regional wall motion. Methods and Results: Twenty hospitals in Japan will participate in the J-WIND-ANP study. Patients with AMI who are candidates for PCI are randomly allocated to receive either i.v. ANP or placebo administration. The primary end-points are (1) estimated infarct size (Σ -creatinine kinase and troponin T) and (2) left ventricular function (left ventriculograms). Single nucleotide polymorphisms (SNPs) that may be associated with the function of ANP and susceptibility of AMI will be examined. Furthermore, a data mining method will be used to design the optimal combinational therapy for post-MI patients. Conclusions: J-WIND-ANP will provide important data on the effects of ANP as an adjunct to PCI for AMI and the SNPs information will open the field of tailor-made therapy. The optimal therapeutic drug combination will also be determined for post-MI patients.

IT 107133-36-8, Perindopril erbumine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug therapy for data mining of cardiovascular therapy combination;
large-scale trial rationale and design using atrial natriuretic peptide
(ANP) as adjunct to PCI for ST-segment elevation acute myocardial
infarction patients)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 39 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:120696 HCAPLUS

DOCUMENT NUMBER: 140:169624

TITLE: Pharmaceutical formulations comprising highly soluble drugs

INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Nadkarni, Sunil Sadanand

PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012699	A2	20040212	WO 2003-IN261	20030801
WO 2004012699	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274680	A1	20040223	AU 2003-274680	20030801
PRIORITY APPLN. INFO.:			IN 2002-MU696	A 20020805
			IN 2002-MU698	A 20020805
			IN 2003-MU81	A 20030122
			WO 2003-IN261	W 20030801
AB The present invention provides a novel modified release dosage form comprising a highly soluble drug, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents and a process for preparing the dosage form. Specifically, the dosage form comprises micro matrix particles containing a highly soluble drug and one or more hydrophobic release controlling agents and coated micro matrix particles with one or more hydrophobic release controlling agents. The invention also relates to the use of dual retard technique to effectively control the release rate of modified release active ingredient by using small quantity of release controlling agents. The invention also provides a novel process for preparing the novel formulations of the invention. The invention further provides a method of treating an animal, particularly a human in need of treatment utilizing the active agents, comprising administering a therapeutically effective amount of composition or solid oral dosage form according to the invention to provide administration of active ingredients.				
IT 107133-36-8, Perindopril erbumine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations comprising highly soluble drugs)				
RN 107133-36-8 HCAPLUS				
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)				
CM 1				
CRN 82834-16-0				
CMF C19 H32 N2 O5				


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 40 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:106709 HCAPLUS

DOCUMENT NUMBER: 140:395632

TITLE: Utilization of maltodextrin based enantioselective, potentiometric membrane electrodes for the enantioselective assay of S-perindopril

AUTHOR(S): Ozoemena, Kenneth I.; Stefan, Raluca-Ioana; van Staden, Jacobus F.; Aboul-Enein, Hassan Y.

CORPORATE SOURCE: Department of Chemistry, University of Pretoria, Pretoria, 0002, S. Afr.

SOURCE: Talanta (2004), 62(4), 681-685

CODEN: TLNTA2; ISSN: 0039-9140

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Enantioselective, potentiometric membrane electrodes (EPMEs) based on carbon paste impregnated with different maltodextrins {dextrose equivalent (DE) 4.0-7.0 (I), 13.0-17.0 (II) and 16.5-19.5 (III)} as chiral selectors for the assay of S-perindopril is described. The proposed electrodes could be reliably employed in the assay of S-perindopril raw material and from its pharmaceutical formulation, Coversyl tablets. The electrode based on maltodextrin (I) showed the best enantioselectivity and time-stability. The surfaces of the electrodes are easily renewable by simply polishing on an alumina paper.

IT 107133-36-8, Coversyl

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(maltodextrin based enantioselective, potentiometric membrane electrodes for the enantioselective assay of S-perindopril)

RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.


with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 41 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:36709 HCAPLUS

DOCUMENT NUMBER: 140:59939

TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts

INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 7 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1380591	A1	20040114	EP 2003-292132	20030829
EP 1380591	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 310012	E	20051215	AT 2003-292132	20030829

WO 2005023842 A1 20050317 WO 2004-FR2197 20040827
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.:


EP 2003-292132

A 20030829

OTHER SOURCE(S):

MARPAT 140:59939

GI



AB A method for the synthesis of perindopril and its tert-Bu amine salt is described. The steps are: coupling of hexahydroindolecarboxylate I with propionyl chloride II in CH₂Cl₂, followed by Boc deprotection with TFA and reaction with Et 2-oxopentanoate and hydrogenation over Pd/C. Addition of tert-butylamine to perindopril provides the salt.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of perindopril and tert-butylamine salt)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0

CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 42 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:36708 HCAPLUS
 DOCUMENT NUMBER: 140:59938
 TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts
 INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre
 PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1380590	A1	20040114	EP 2003-292131	20030829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005023841	A1	20050317	WO 2004-FR2196	20040827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-292131 A 20030829

OTHER SOURCE(S): MARPAT 140:59938

AB A method for the synthesis of perindopril and its pharmaceutically-acceptable salts involves coupling of (2S)-2,3,4,5,6,7-hexahydro-1H-indolecarboxylic acid or its benzyl ester with R²-L-Ala-X (R² is a protective group, X is halo), followed by deprotection, reaction with (R)-PrCH(G)CO₂Et (G is Cl, Br, I, or tosyloxy), and catalytic hydrogenation. Addition of tert-butylamine to perindopril provides the salt.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of perindopril and tert-butylamine salt)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 43 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:1007353 HCAPLUS

DOCUMENT NUMBER: 140:47547

TITLE: Microcapsules for delayed and controlled release of perindopril

INVENTOR(S): Huet de Barochez, Bruno; Wuthrich, Patrick; Legrand, Valerie; Castan, Catherine; Meyrueix, Remi

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Fr. Demande, 26 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

FR 2841140	A1	20031226	FR 2002-7778	20020624
FR 2841140	B1	20041001		
CA 2491172	AA	20031231	CA 2003-2491172	20030624
WO 2004000286	A1	20031231	WO 2003-FR1931	20030624

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003260620	A1	20040106	AU 2003-260620	20030624
BR 2003012026	A	20050322	BR 2003-12026	20030624
EP 1515704	A1	20050323	EP 2003-760778	20030624

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005533079	T2	20051104	JP 2004-514980	20030624
NO 2005000163	A	20050112	NO 2005-163	20050112

PRIORITY APPLN. INFO.: FR 2002-7778 A 20020624
WO 2003-FR1931 W 20030624

AB Microcapsules allowing the delayed and controlled release of perindopril, or one of its salts, intended for oral administration is prepared
Microcapsules were made from tert-butylamine perindopril 700, Eudargit L100 37, and hydrogenated palm oil 56 g and their dissoln. rates were studied.

IT 107133-36-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcapsules for delayed and controlled release of perindopril)


RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 44 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:985781 HCAPLUS

DOCUMENT NUMBER: 140:28049

TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts [2003/26]

INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1371659	A1	20031217	EP 2003-292133	20030829
EP 1371659	B1	20051012		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 306496	E	20051015	AT 2003-292133	20030829
WO 2005023843	A1	20050317	WO 2004-FR2198	20040827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-292133 A 20030829

OTHER SOURCE(S): MARPAT 140:28049

GI



AB A method for the synthesis of perindopril (I) and its tert-Bu amine salt is described. The steps are: coupling of (hexahydro)indolecarboxylate II with propionyl chloride III in CH_2Cl_2 , followed by Boc deprotection with TFA, reaction with Et 2-oxopentanoate under reductive conditions, and removal of benzyl ester by hydrogenation to give I. Addition of tert-Bu amine to I provides the salt.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of perindopril and its tert-Bu amine salt)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 45 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:947713 HCAPLUS

DOCUMENT NUMBER: 139:381760

TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts

INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1367061	A1	20031203	EP 2003-291601	20030630
EP 1367061	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 315043	E	20060215	AT 2003-291601	20030630
AU 2004253721	A1	20050113	AU 2004-253721	20040628
WO 2005003153	A1	20050113	WO 2004-FR1637	20040628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-291601 A 20030630
WO 2004-FR1637 W 20040628

OTHER SOURCE(S): CASREACT 139:381760; MARPAT 139:381760

AB A method for the synthesis of perindopril and its pharmaceutically-acceptable salts (e.g., the tert-butylamine) involves cyclocondensation reaction of N-[(S)-1-carbethoxybutyl]-(S)-alanine with sulfinyl chlorides R1SOCl (R1 = imidazolyl, benimidazolyl, or tetrazolyl) to give Et (2S)-2-[(4S)-4-methyl-2,5-dioxo-1,2,3-oxathiazolidin-3-yl]pentanoate, which is amidated with (2S)-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid and hydrogenated over 10% Pt/C to give perindopril.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)


(synthesis of perindopril via cyclocondensation of carbethoxybutylalanine with imidazolesulfinyl chloride)

RN 107133-36-8 HCAPLUS
 CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0
 CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
 CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 46 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:909172 HCAPLUS
 DOCUMENT NUMBER: 139:396166
 TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts
 INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre
 PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
 SOURCE: Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1362864	A1	20031119	EP 2003-291600	20030630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 AU 2004255899 A1 20050120 AU 2004-255899 20040628
 WO 2005005461 A2 20050120 WO 2004-FR1638 20040628
 WO 2005005461 A3 20050331

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.:

EP 2003-291600 A 20030630

WO 2004-FR1638 W 20040628

OTHER SOURCE(S): CASREACT 139:396166; MARPAT 139:396166

AB Perindopril and its pharmaceutically acceptable salts (e.g., tert-butylamine salt) are prepared by the cyclocondensation reaction of N-[(S)-carboethoxy-1-butyl]-(S)-alanine with a carbonyl compound X1COX2 (X1, X2 = leaving group; e.g., 1,1'-carbonyldiimidazole) to give Et (2S)-2-[(4S)-4-Methyl-2,5-dioxo-1,3-oxazolidin-3-yl]pentanoate which is amidated with (2S)-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid in the presence of an acid (e.g., hydrochloric acid) to give (2S)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid which is hydrogenated with a 10% Pt/C catalyst to give perindopril which is then salified with tert-butylamine to give perindopril tert-butylammonium salt.

IT 107133-36-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (method for synthesis of perindopril and its pharmaceutically acceptable salts)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0


CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 47 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:609507 HCAPLUS

DOCUMENT NUMBER: 139:149930

TITLE: Process for the preparation of high purity perindopril and intermediates useful in its synthesis

INVENTOR(S): Simig, Gyula; Mezei, Tibor; Porcs-Makkay, Marta; Mandi, Attila

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1333026	A1	20030806	EP 2002-290206	20020130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2474003	AA	20030807	CA 2003-2474003	20030129
WO 2003064388	A2	20030807	WO 2003-IB691	20030129
WO 2003064388	A3	20040205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200400107	A	20041015	EE 2004-107	20030129
BR 2003007293	A	20041221	BR 2003-7293	20030129
US 2005119492	A1	20050602	US 2003-503272	20030129
JP 2005521667	T2	20050721	JP 2003-564011	20030129
NO 2004003472	A	20040820	NO 2004-3472	20040820
BG 108858	A	20050531	BG 2004-108858	20040827
PRIORITY APPLN. INFO.:			EP 2002-290206	A 20020130
			WO 2003-IB691	W 20030129

OTHER SOURCE(S): MARPAT 139:149930

AB The invention relates to 1-[2(S)-[1(S)-(ethoxycarbonyl)butylaminolpropiony 1]- (3aS,7aS)octahydroindole-2(S)-carboxylic acid (perindopril) and its

tert-butylamine salt, free of contaminants derivable from dicyclohexylcarbodiimide, and a process for their synthesis. The invention also relates to N-[1-(ethoxycarbonyl)butyl]-N-(alkoxycarbonyl)alanine intermediates used in the synthesis of perindopril, a known ACE inhibitor. Thus, N-[1-(ethoxycarbonyl)butyl]-N-(ethoxycarbonyl)alanine, prepared by ethoxycarbonylation of N-[1-(ethoxycarbonyl)butyl]alanine, was treated with thionyl chloride in CH₂Cl₂ and acylated by perhydroindole-2-carboxylic acid in THF at reflux for 4-4.5 h. The product was treated with tert-butylamine to afford 55% perindopril ebumine.

IT 107133-36-8P, Perindopril ebumine

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for preparation of high purity perindopril and intermediates useful in its synthesis)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 48 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:595532 HCAPLUS

DOCUMENT NUMBER: 139:312571

TITLE: Utility of copper(II) oxide as a packed reactor in flow injection assembly for rapid analysis of some angiotensin converting enzyme inhibitors

AUTHOR(S): Emara, Samy; El-Gindy, Alaa; El-Shorbagi, Abdel-Nasser; Hadad, Ghada

CORPORATE SOURCE: Faculty of Pharmacy, Department of Analytical Pharmaceutical Chemistry, Suez Canal University, Ismailia, 41522, Egypt

SOURCE: Analytica Chimica Acta (2003), 489(1), 115-123
CODEN: ACACAM; ISSN: 0003-2670

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new simple, sensitive, rapid and precise flow injection (FI) procedure based on the formation of copper complexes with some angiotensin converting enzyme (ACE) inhibitors has been developed and evaluated for the anal. of lisinopril (LN), enalapril maleate (EP), ramipril (RP) and perindopril tert-butylamine (PD). In this method, samples were injected into a flowing stream of distilled-deionized water, carried through the packed reactor of CuO for derivatization followed by UV detection. The flow rate was 1.5 mL min⁻¹ and column temperature was ambient (25 °C). Lisinopril was injected directly into the flowing stream and the detector response was measured at 262 nm. The hydrolysis products of enalapril maleate, ramipril and perindopril tert-butylamine in 0.2N NaOH were injected after neutralization with 1N HCl and the detector response was measured at 272, 265 and 252 nm, resp. The developed method was successfully applied to the determination of tested drugs in pharmaceutical preps. at a sampling rate of 60 samples h⁻¹ and a recovery near 100% for all compds.

IT 107133-36-8
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(copper(II) oxide as a packed reactor in flow injection assembly for rapid anal. of some angiotensin converting enzyme inhibitors)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0

CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 49 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:573218 HCAPLUS

DOCUMENT NUMBER: 139:122793

TITLE: Oral pharmaceutical composition containing perindopril

INVENTOR(S): Wuthrich, Patrick; Rolland, Herve; Julien, Marc

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Fr. Demande, 11 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2834893	A1	20030725	FR 2002-790	20020123
FR 2834893	B1	20040227		
CA 2473205	AA	20030731	CA 2003-2473205	20030122
WO 2003061691	A1	20030731	WO 2003-FR200	20030122
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1467750	A1	20041020	EP 2003-731736	20030122
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007048	A	20041026	BR 2003-7048	20030122
US 2005106237	A1	20050519	US 2003-502479	20030122
JP 2005523256	T2	20050804	JP 2003-561634	20030122
CN 1658898	A	20050824	CN 2003-802519	20030122
NZ 533821	A	20050826	NZ 2003-533821	20030122
ZA 2004005009	A	20050624	ZA 2004-5009	20040624
NO 2004003473	A	20040820	NO 2004-3473	20040820
PRIORITY APPLN. INFO.:			FR 2002-790	A 20020123
			WO 2003-FR200	W 20030122


AB An oral dispersible solid pharmaceutical composition contains perindopril, lactose, and starch. A tablet contained perindopril tert-butylamine 4,

Starlac 94, sodium stearyl fumarate 1.5, and colloidal silica 0.5 mg.
 IT 107133-36-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral pharmaceutical composition containing perindopril)
 RN 107133-36-8 HCAPLUS
 CN 1H-Indole-2-carboxylic acid; 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
 with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 82834-16-0
 CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2
 CRN 75-64-9
 CMF C4 H11 N




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 50 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:570833 HCAPLUS
 DOCUMENT NUMBER: 139:111682
 TITLE: Combined use of a GLP-1 compound and a modulator of
 diabetic late complications
 INVENTOR(S): Knudsen, Lotte Bjerre; Selmer, Johan
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059372	A2	20030724	WO 2002-DK888	20021220
WO 2003059372	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002351753	A1	20030730	AU 2002-351753	20021220
EP 1461070	A2	20040929	EP 2002-787467	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516968	T2	20050609	JP 2003-559533	20021220
US 2003144206	A1	20030731	US 2002-328282	20021223
PRIORITY APPLN. INFO.:				
			DK 2001-1969	A 20011229
			DK 2002-760	A 20020517
			DK 2001-969	A 20011229
			US 2002-350087P	P 20020117
			WO 2002-DK888	W 20021220
AB	Methods and uses for treatment of diabetic late complications comprising administration of a GLP-1 compound and a modulator of diabetic complications.			
IT	107133-36-8, Perindopril erbumine			
RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(combined use of a GLP-1 compound and a modulator of diabetic late complications)			
RN	107133-36-8 HCAPLUS			
CN	1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)			
CM	1			
CRN	82834-16-0			
CMF	C19 H32 N2 O5			

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



L17 ANSWER 51 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:488613 HCAPLUS

DOCUMENT NUMBER: 139:22503

TITLE: Method for the synthesis of perindopril and its pharmaceutically-acceptable salts

INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-pierre

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1321471	A1	20030625	EP 2003-290605	20030312
EP 1321471	B1	20050504		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 294814	E	20050515	AT 2003-290605	20030312
PT 1321471	T	20050729	PT 2003-290605	20030312
ES 2240919	T3	20051016	ES 2003-3290605	20030312
WO 2004083238	A1	20040930	WO 2004-FR594	20040312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2003-290605 A 20030312

OTHER SOURCE(S): CASREACT 139:22503; MARPAT 139:22503

AB Perindopril and its pharmaceutically-acceptable salts were prepared from 2,7-oxepanedione by a multistep procedure, i.e., reaction with (R)-XCH₂CH(NHBoc)CO₂CH₂Ph (X is Br or iodo; Boc is tert-butoxycarbonyl), cyclization of deprotected 2-amino-4-oxononanedioic acid derivative, Ti-catalyzed coupling to form the indole ring system, reaction with N-[(S)-1-carbethoxybutyl]-(S)-alanine, and catalytic hydrogenation. In an example, perindopril was obtained with enantiomeric purity 99%.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)

(method for synthesis of perindopril and its pharmaceutically-acceptable salts)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 52 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:319257 HCAPLUS

DOCUMENT NUMBER: 138:343856

TITLE: Buccal sprays or capsules containing cardiovascular or renal drugs

INVENTOR(S): Dugger, Harry A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 19

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077229	A1	20030424	US 2002-230075	20020829
WO 9916417	A1	19990408	WO 1997-US17899	19971001
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1029536	A1	20000823	EP 2000-109347	19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1036561	A1	20000920	EP 2000-109357	19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2496769	AA	20040311	CA 2003-2496769	20030827
WO 2004019909	A2	20040311	WO 2003-US26853	20030827
WO 2004019909	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003270014	A1	20040319	AU 2003-270014	20030827
EP 1536769	A2	20050608	EP 2003-751909	20030827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006502147	T2	20060119	JP 2004-531569	20030827
US 2005025713	A1	20050203	US 2004-928979	20040827
PRIORITY APPLN. INFO.:				
			WO 1997-US17899	A2 19971001
			US 2000-537118	A2 20000329
			EP 1997-911621	A3 19971001
			US 2002-230075	A 20020829
			WO 2003-US26853	W 20030827

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a polar lingual spray contained isoproterenol-HCl 0.5-6, water 50-75, EtOH 5-10, PEG 5-15, sorbitol 0.4-1.0, aspartame 0.04-0.1, and flavors 2-3%.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(buccal sprays or capsules containing cardiovascular or renal drugs)

RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.


CM 1

CMF C19 H32 'N2 05

Chemical structure of compound 10, a 1,4-dithiane derivative. The structure shows a 1,4-dithiane ring with a cyclohexyl group at position 2 and a carboxylic acid group at position 5. The nitrogen at position 3 is substituted with a 2-methyl-2-(n-propylamino)acetyl group. Stereochemistry is indicated with wedges and dashes.

CM 2

CMF C4 H11 N



ACCESSION NUMBER: 2003:173469 HCAPLUS

DOCUMENT NUMBER: . . 138:215307

TITLE: Drugs containing chymase inhibitor and ACE inhibitor
as the active ingredients

INVENTOR(S): Urata, Hidenori; Hase, Naoki; Tsuchiya, Naoki

PATENT ASSIGNEE(S): Teijin Limited, Japan

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018061	A1	20030306	WO 2002-JP8572	20020826
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,			

RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 CA 2442761 AA 20030306 CA 2002-2442761 20020826
 EP 1419785 A1 20040519 EP 2002-760743 20020826
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 CN 1520314 A 20040811 CN 2002-812646 20020826
 US 2004122042 A1 20040624 US 2003-474334 20031008
 PRIORITY APPLN. INFO.: JP 2001-254120 A 20010824
 WO 2002-JP8572 W 20020826

OTHER SOURCE(S): MARPAT 138:215307

AB It is intended to provide drugs efficacious in treating hypertension, heart diseases (megalocardia, heart failure, myocardial infarction, etc.), cerebral attack, nephritis and the like. Namely, remedies for circulatory diseases wherein a chymase inhibitor and an ACE inhibitor can be used together; and a method of treating circulatory diseases associated with the simultaneous occurrence of chymase inhibition and ACE inhibition.

IT 107133-36-8, Perindopril erbumine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drugs containing chymase inhibitor and ACE inhibitor as the active ingredients for treatment of cardiovascular diseases).

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 54 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:77804 HCAPLUS

DOCUMENT NUMBER: 138:107004

TITLE: A process for the preparation of perindopril, its analogs and salts using 2,5-dioxooxazolidine intermediate compounds

INVENTOR(S): Cid, Pau

PATENT ASSIGNEE(S): Adir, Fr.

SOURCE: Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1279665	A2	20030129	EP 2002-16262	20020723
EP 1279665	A3	20030312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2003010142	A2	20030206	WO 2002-EP8223	20020723
WO 2003010142	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2002011422	A	20040817	BR 2002-11422	20020723
CN 1529694	A	20040915	CN 2002-814322	20020723
JP 2005501829	T2	20050120	JP 2003-515501	20020723
ZA 2004000323	A	20050117	ZA 2004-323	20040115
US 2004248814	A1	20041209	US 2004-484672	20040712
PRIORITY APPLN. INFO.:			EP 2001-500197	A 20010724
			WO 2002-EP8223	W 20020723

OTHER SOURCE(S): MARPAT 138:107004

AB Perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] or its analogs or salts were prepared by treating $\text{RcCH}(\text{CO}_2\text{Ra})\text{NHCHRbCO}_2\text{H}$ (Ra , Rb = C1-4 alkyl, Rc = C1-6alkyl) with $\text{X}_2\text{C}=\text{O}$ (X is a leaving group) to give a 2,5-dioxooxazolidine, which reacts with octahydro-1H-indole-2-carboxylic acid or ester to give the desired product. In an example, N,N'-carbonyldiimidazole was added to a suspension of N-[(S)-1-carbethoxybutyl]-(S)-alanine in CH_2Cl_2 and the mixture kept at 0° for

1 h. (2S,3aS,7aS)-octahydroindole-2-carboxylic acid was added at -5°C and the solution kept at this temperature for 1 h to give 80% perindopril (isolated as the tert-butylamine salt).

IT 107133-36-8P, Perindopril erbumine

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(process for preparation of perindopril using dioxooxazolidine intermediate)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 55 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:971053 HCAPLUS

DOCUMENT NUMBER: 138:33361

TITLE: Stroke recurrence inhibitor

INVENTOR(S): Ishigai, Hiroshi; Mori, Tomohiro; Shibano, Toshiro

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002370981	A2	20021224	JP 2001-178232	20010613
PRIORITY APPLN. INFO.:			JP 2001-178232	20010613

OTHER SOURCE(S): MARPAT 138:33361

AB Claimed is a stroke recurrence inhibitor containing an octahydroindole-2-carboxylic derivative (Markush structure given) as active ingredient. Also claimed is a stroke recurrence inhibitor containing perindopril as active ingredient. Also claimed is a stroke recurrence inhibitor containing perindopril erbumine as active ingredient. The bioactivities of perindopril erbumine were demonstrated.

IT 107133-36-8, Perindopril erbumine
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (bioeffect of perindopril as stroke recurrence inhibitor)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 56 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:964185 HCAPLUS


DOCUMENT NUMBER: 138:19502

TITLE: Combination of a PTPase inhibitor and an ACE inhibitor to lower the risk of cardiovascular disease and

cardiovascular events in a mammal experiencing or
subject to type II diabetes or syndrome X
INVENTOR(S): Zhang, Danyi; Meng, Xu; Kotake, Alvin Norio
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100398	A1	20021219	WO 2002-US17940	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003055058	A1	20030320	US 2002-163704	20020606
PRIORITY APPLN. INFO.:			US 2001-296466P	P 20010607
OTHER SOURCE(S): MARPAT 138:19502				
AB The invention relates to pharmaceutical compns. and methods of treatment using a PTPase (protein-tyrosine phosphatase) inhibitor and an angiotensin converting enzyme (ACE) inhibitor to lower the risk of cardiovascular disease and cardiovascular events in a mammal experiencing or subject to type II diabetes (non-insulin-dependent diabetes mellitus), preferably in human type II diabetics, or syndrome X.				
IT 107133-36-8, Perindopril-tert-butylamine RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (PTPase inhibitor-ACE inhibitor combination to lower risk of cardiovascular disease or cardiovascular event in mammal experiencing or subject to type II diabetes or syndrome X)				
RN 107133-36-8 HCAPLUS				
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1- (ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)				
CM 1				
CRN 82834-16-0				
CMF C19 H32 N2 O5				


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 57 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:574955 HCAPLUS

DOCUMENT NUMBER: 137:129903

TITLE: Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions

INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058731	A2	20020801	WO 2002-US1196	20020125
WO 2002058731	A3	20031120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2434436	AA	20020801	CA 2002-2434436	20020125

US 2003069221	A1	20030410	US 2002-57339	20020125
EP 1385548	A2	20040204	EP 2002-707500	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006644	A	20040225	BR 2002-6644	20020125
EP 1413331	A2	20040428	EP 2004-161	20020125
EP 1413331	A3	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517919	T2	20040617	JP 2002-559065	20020125
CN 1582168	A	20050216	CN 2002-804219	20020125
EP 1541175	A2	20050615	EP 2005-3029	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003005692	A	20041025	ZA 2003-5692	20030723
ZA 2003005694	A	20041025	ZA 2003-5694	20030723
ZA 2003005693	A	20050209	ZA 2003-5693	20030723
NO 2003003358	A	20030912	NO 2003-3358	20030725
US 2004097482	A1	20040520	US 2003-639900	20030813
US 2005153952	A1	20050714	US 2004-998400	20041129
PRIORITY APPLN. INFO.:				
			US 2001-264275P	P 20010126
			US 2001-264396P	P 20010126
			US 2001-264600P	P 20010126
			US 2001-323842P	P 20010921
			US 2001-323839P	P 20010921
			EP 2002-707500	A3 20020125
			EP 2002-714773	A3 20020125
			US 2002-57323	A3 20020125
			US 2002-57646	A1 20020125
			WO 2002-US1196	W 20020125
			US 2002-136968	A3 20020501

OTHER SOURCE(S): MARPAT 137:129903
GI



- AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.

IT 107133-36-8, Perindopril erbumine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of azetidinone sterol absorption inhibitor(s) with
cardiovascular agent(s) for the treatment of vascular conditions)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 58 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:504616 HCAPLUS

DOCUMENT NUMBER: 137:68194

TITLE: Thermoformable solid pharmaceutical composition for controlled release of perindopril

INVENTOR(S): Wuthrich, Patrick; Rolland, Herve; Briault, Gilles; Pichon, Gérard; Tharrault, Francois

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND . DATE

APPLICATION NO.

DATE

WO 2002051407	A1	20020704	WO 2001-FR4133	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2818550	A1	20020628	FR 2000-17013	20001226
FR 2818550	B1	20030207		
CA 2432896	AA	20020704	CA 2001-2432896	20011221
EP 1345605	A1	20030924	EP 2001-989653	20011221
EP 1345605	B1	20050720		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016536	A	20031021	BR 2001-16536	20011221
JP 2004518666	T2	20040624	JP 2002-552552	20011221
NZ 526405	A	20041224	NZ 2001-526405	20011221
AT 299704	E	20050815	AT 2001-989653	20011221
PT 1345605	T	20051130	PT 2001-989653	20011221
ES 2244672	T3	20051216	ES 2001-1989653	20011221
ZA 2003004405	A	20040625	ZA 2003-4405	20030605
NO 2003002738	A	20030616	NO 2003-2738	20030616
US 2004115227	A1	20040617	US 2003-451937	20030626
HK 1063739	A1	20060113	HK 2004-106635	20040903
PRIORITY APPLN. INFO.:			FR 2000-17013	A 20001226
			WO 2001-FR4133	W 20011221

AB The invention concerns a novel solid pharmaceutical composition, with controlled release, obtained by hot-process thermoforming of a mixture based on polymers belonging to the polymethacrylate family, and perindopril or one of its pharmaceutically acceptable salts. Controlled-release pharmaceutical were prepared by extrusion of 2% perindopril tert-butylamine salt and 98% Eudragit E-100 at 95°. Dissoln. rate of the composition was studied.

IT 107133-36-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermoformable solid pharmaceutical composition for controlled release of perindopril)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 59 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:851113 HCAPLUS

DOCUMENT NUMBER: 135:371632

TITLE: Preparation of the ACE-inhibiting β -crystalline form of perindopril tert-butylamine salt and antihypertensive pharmaceutical formulation containing it

INVENTOR(S): Pfeiffer, Bruno; Ginot, Yves-Michel; Coquerel, Gerard; Beilles, Stephane

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087836	A1	20011122	WO 2001-FR2168	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2811319	A1	20020111	FR 2000-8792	20000706

FR 2811319	B1	20020823		
CA 2415442	AA	20011122	CA 2001-2415442	20010706
EP 1294689	A1	20030326	EP 2001-954059	20010706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012244	A	20030624	BR 2001-12244	20010706
JP 2003533508	T2	20031111	JP 2001-584233	20010706
JP 3592297	B2	20041124		
EE 200300002	A	20040816	EE 2003-2	20010706
NZ 523234	A	20050128	NZ 2001-523234	20010706
US 2004029813	A1	20040212	US 2002-312902	20021231
ZA 2003000024	A	20040205	ZA 2003-24	20030102
NO 2003000050	A	20030106	NO 2003-50	20030106
BG 107533	A	20031128	BG 2003-107533	20030205
HR 2003000079	A1	20030430	HR 2003-79	20030206
JP 2005002121	A2	20050106	JP 2004-206159	20040713
US 2005203165	A1	20050915	US 2005-52489	20050204

PRIORITY APPLN. INFO.:

FR 2000-8792	A	20000706
JP 2001-584233	A3	20010706
WO 2001-FR2168	W	20010706
US 2002-312902	B1	20021231

AB The more-stable β -crystalline form of the tert-butylamine salt of perindopril (I), characterized by its X-ray powder diffraction pattern, is prepared by refluxing the tert-butylamine salt of perindopril in dichloromethane, followed by cooling the mixture, and filtration. A I-contg tablet formulation is presented.

IT 107133-36-8

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (preparation of the ACE-inhibiting β -crystalline form of perindopril tert-butylamine salt and antihypertensive pharmaceutical formulation containing it)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0


CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 60 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:851112 HCAPLUS

DOCUMENT NUMBER: 135:371631

TITLE: Preparation and X-ray characterization of the ACE-inhibiting α -crystalline form of the tert-butylamine salt of perindopril

INVENTOR(S): Pfeiffer, Bruno; Ginot, Yves-Michel; Coquerel, Gerard; Beilles, Stephane

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087835	A1	20011122	WO 2001-FR2167	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2811320	A1	20020111	FR 2000-8793	20000706
FR 2811320	B1	20020823		
CA 2415438	AA	20011122	CA 2001-2415438	20010706
EP 1296947	A1	20030402	EP 2001-954058	20010706
EP 1296947	B1	20040204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012367	A	20030513	BR 2001-12367	20010706
JP 2003533507	T2	20031111	JP 2001-584232	20010706
JP 3602826	B2	20041215		
AT 258918	E	20040215	AT 2001-954058	20010706
NZ 523173	A	20040430	NZ 2001-523173	20010706
PT 1296947	T	20040531	PT 2001-954058	20010706
EE 200300001	A	20040816	EE 2003-1	20010706
ES 2214434	T3	20040916	ES 2001-1954058	20010706
ZA 2002010092	A	20031212	ZA 2002-10092	20021212
US 2003186896	A1	20031002	US 2002-312961	20021231

S-118

NO 2003000024	A	20030103	NO 2003-24	20030103
BG 107532	A	20031231	BG 2003-107532	20030205
HR 2003000077	A1	20030430	HR 2003-77	20030206
US 2005059609	A1	20050317	US 2004-792355	20040303
JP 2005047902	A2	20050224	JP 2004-206158	20040713
PRIORITY APPLN. INFO.:			FR 2000-8793	A 20000706
			FR 2000-8973	A 20000706
			JP 2001-584232	A3 20010706
			WO 2001-FR2167	W 20010706
			US 2002-312961	B1 20021231

AB The α -crystalline form of the ACE-inhibiting tert-butylamine salt of perindopril (I) is prepared by refluxing the tert-butylamine salt of perindopril in Et acetate, cooling the mixture, and filtering the I α -crystal modification, which is characterized by its powder X-ray diffraction pattern, and a I-containing pharmaceutical formulation is prepared

IT 107133-36-8, Perindopril erbumine

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (preparation and X-ray characterization of the ACE-inhibiting α -crystalline form of the tert-butylamine salt of perindopril)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 61 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:816626 HCAPLUS

DOCUMENT NUMBER: 135:344373

TITLE: Process for preparing the novel γ crystalline form of the diuretic perindopril tert-butylamine salt
 INVENTOR(S): Pfeiffer, Bruno; Ginot, Yves-Michel; Coquerel, Gerard; Beilles, Stephane

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083439	A2	20011108	WO 2001-FR2169	20010706
WO 2001083439	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2811318	A1	20020111	FR 2000-8791	20000706
FR 2811318	B1	20020823		
CA 2415447	AA	20011108	CA 2001-2415447	20010706
AU 2001076420	A5	20011112	AU 2001-76420	20010706
EP 1296948	A2	20030402	EP 2001-954060	20010706
EP 1296948	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012211	A	20030506	BR 2001-12211	20010706
AT 249435	E	20030915	AT 2001-954060	20010706
JP 2003531890	T2	20031028	JP 2001-580868	20010706
JP 3592296	B2	20041124		
PT 1296948	T	20031231	PT 2001-954060	20010706
ES 2206423	T3	20040516	ES 2001-1954060	20010706
NZ 523311	A	20040625	NZ 2001-523311	20010706
EE 200300003	A	20040816	EE 2003-3	20010706
US 2003158121	A1	20030821	US 2002-312903	20021231
ZA 2003000025	A	20040210	ZA 2003-25	20030102
NO 2003000051	A	20030106	NO 2003-51	20030106
BG 107534	A	20031231	BG 2003-107534	20030205
HR 2003000078	A1	20030430	HR 2003-78	20030206
HR 20030078	B1	20040630		
US 2004248817	A1	20041209	US 2004-811727	20040329
JP 2005002120	A2	20050106	JP 2004-206157	20040713
PRIORITY APPLN. INFO.:				
			FR 2000-8791	A 20000706
			JP 2001-580868	A3 20010706
			WO 2001-FR2169	W 20010706
			US 2002-312903	B1 20021231

AB The γ crystalline form of the diuretic perindopril tert-butylamine salt

(I) is prepared by refluxing a chloroform-I solution, cooling the solution to 0°, and filtering the I. γ crystal modification which is characterized by its X-ray diffraction pattern; a I-containing formulation is presented.

IT 107133-36-8

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)

(process for preparing the novel γ crystalline form of the diuretic perindopril tert-butylamine salt)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 62 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:782126 HCAPLUS

DOCUMENT NUMBER: 137:15299

TITLE: Activity of the renin-angiotensin-aldosterone system and its impact of the efficiency of treatment in pulmonary tuberculosis patients with chronic heart failure

AUTHOR(S): Radzevich, A. E.; Dityatkov, A. E.; Tikhonov, V. A.

CORPORATE SOURCE: Protivotuberkulozniy Klin. Dispanzer No. 12., Mosk. Gos. Mediko-Stomatol. Univ., Moscow, Russia

SOURCE: Problemy Tuberkuleza (2001), (5), 16-19

CODEN: PRTUAX; ISSN: 0032-9533
PUBLISHER: Izdatel'stvo Meditsina
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The renin-angiotensin-aldosterone system (RAAS) was studied in 93 patients with pulmonary tuberculosis complicated by chronic heart failure (CHF). RIA was used to determine plasma renin activity (PRA) and serum angiotensin I and aldosterone levels. There was higher RAAS activity, as shown by elevated PRA. RAAS activity decreased during CHF treatment with angiotensin-converting enzyme inhibitors (captopril, ramipril, prestarium) and an angiotensin II-receptor blocker (cozaar), which is indicative of the efficiency of CHF treatment.

IT 107133-36-8, Prestarium

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(activity of the RAAS and its impact of RAAS efficiency of treatment in pulmonary tuberculosis patients complicated by chronic heart failure)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 63 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:597957 HCAPLUS
DOCUMENT NUMBER: 135:167034

TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts
 INVENTOR(S): Langlois, Pascal; Turbe, Hugues
 PATENT ASSIGNEE(S): Adir et Compagnie, Fr.
 SOURCE: PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058868	A1	20010816	WO 2001-FR1026	20010405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2807431	A1	20011012	FR 2000-4379	20000406
FR 2807431	B1	20020719		
CA 2405486	AA	20010816	CA 2001-2405486	20010405
AU 2001048470	A5	20010820	AU 2001-48470	20010405
EP 1268424	A1	20030102	EP 2001-921486	20010405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009836	A	20030624	BR 2001-9836	20010405
JP 2003531825	T2	20031028	JP 2001-558419	20010405
NZ 521454	A	20040326	NZ 2001-521454	20010405
EE 200200575	A	20040415	EE 2002-575	20010405
ZA 2002007419	A	20030916	ZA 2002-7419	20020916
US 2003069431	A1	20030410	US 2002-239129	20020919
US 6835843	B2	20041228		
NO 2002004808	A	20021004	NO 2002-4808	20021004
BG 107249	A	20030731	BG 2002-107249	20021104
PRIORITY APPLN. INFO.:			FR 2000-4379	A 20000406
			WO 2001-FR1026	W 20010405

OTHER SOURCE(S): CASREACT 135:167034

AB Perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] was prepared by coupling (2S,3aS,7aS)octahydroindole-2-carboxylic acid tosylate with N-[(S)-1-carbethoxybutyl]-(S)-alanine, followed by catalytic hydrogenation to remove the benzyl group. In an example, the coupling reaction was carried out in Et acetate in the presence of Et₃N, 1-hydroxybenzotriazole and dicyclohexylcarbodiimide at 30° for 3h to give 92% perindopril benzyl ester.

IT 107133-36-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (method for synthesis of perindopril)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 64 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:466243 HCAPLUS

DOCUMENT NUMBER: 135:266539

TITLE: Perindopril. An updated review of its use in hypertension

AUTHOR(S): Hurst, Miriam; Jarvis, Blair

CORPORATE SOURCE: Adis International Limited, Auckland, N. Z.

SOURCE: Drugs (2001), 61(6), 867-896
CODEN: DRUGAY; ISSN: 0012-6667

PUBLISHER: Adis International Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 127 refs. Perindopril erbumine (perindopril) is a prodrug ester of perindoprilat, an angiotensin converting enzyme (ACE) inhibitor. Perindopril 4 to 8mg once daily significantly reduces supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline values in hypertensive patients. These redns. are maintained for at least 24 h, as evidenced by trough/peak ratios of >50%. Vascular abnormalities associated with hypertension were improved or normalized during perindopril treatment. Perindopril 4 to 8mg once daily significantly decreased carotid-femoral aortic pulse wave velocity (PWV), improved arterial compliance, reduced left ventricular mass index and, in patients with recent cerebral ischemia and/or stroke, preserved cerebral blood flow

despite significantly reducing SBP and DBP. Further research is needed to establish the significance of promising results showing that redns. in aortic PWV were associated with reduced mortality in patients with end-stage renal failure, a third of whom received perindopril. Response rates (nos. of patients with supine DBP ≤ 90 mm Hg) were significantly higher with perindopril 4 to 8 mg once daily (67 to 80%) than with captopril 25 to 50 mg twice daily (44 to 57%) in 3 randomized double-blind trials. In other clin. trials, the antihypertensive effects of perindopril were similar to those of other ACE inhibitors (including enalapril) and calcium-channel antagonists. Combination treatment with perindopril and an antihypertensive agent from another treatment class provided addnl. benefits, either as first-line treatment or in patients failing to respond to monotherapy. Perindopril monotherapy was also effective in the elderly and in patients with hypertension and concomitant disease. Perindopril has a similar adverse event profile to that of other ACE inhibitors; cough is the most common event reported during treatment, and is also the most common adverse event responsible for treatment withdrawal. In conclusions, perindopril is a well tolerated ACE inhibitor that is significantly better than captopril (in terms of response rates) in the treatment of hypertension, and as effective as other ACE inhibitors. Perindopril appears to reverse some of the vascular abnormalities associated with hypertension, including arterial stiffness and left ventricular hypertrophy, although further research is needed to confirm promising results regarding its ability to decrease associated cardiovascular morbidity and mortality. Results from ongoing studies will help confirm the place of perindopril in the treatment of hypertension; currently, it is an effective and well tolerated treatment for patients with mild to moderate essential hypertension.

IT 107133-36-8, Perindopril erbumine

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(perindopril in treatment of hypertension in humans)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0


CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 127 THERE ARE 127 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 65 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:324422 HCAPLUS

DOCUMENT NUMBER: 134:336208

TITLE: Antitumor agents and neovascularization inhibitors containing perindopril erbumines

INVENTOR(S): Fukui, Hiroshi; Kichiji, Hitoshi

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001122780	A2	20010508	JP 1999-307814	19991028
PRIORITY APPLN. INFO.:			JP 1999-307814	19991028
OTHER SOURCE(S):	MARPAT	134:336208		

GI



AB Pharmaceuticals, useful for inhibition of proliferation and/or metastasis of malignant tumor or neovascularization, contain perindopril erbumine derivs. I [ring A = saturated ring; n = 0; R1 = C1-4 (amino)alkyl; R2 = H, C1-4 alkyl; R3 = C≤9 (chloro)alkyl, CH2SCHR4R5; R4 = H, C1-4 alkyl; R5 = alkoxy carbonyl; R4 = R5 = C3-6 cycloalkyl; q = 0]. Perindopril erbumine (at 2 mg/kg) inhibited proliferation of liver cancer cells in mouse.

IT 107133-36-8, Perindopril erbumine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor agents and neovascularization inhibitors containing perindopril

erbumines)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 66 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:875595 HCAPLUS

DOCUMENT NUMBER: 135:86714

TITLE: Butylaminiperindopril decreases transforming growth factor- β 1 messenger RNA production in lungs of C57BL6 mice after low-dose whole-body irradiation

AUTHOR(S): Olejar, T.; Pouckova, P.; Zadinova, M.

CORPORATE SOURCE: Institute of Biophysics, Charles University, Prague, Czech Rep.

SOURCE: Drugs under Experimental and Clinical Research (2000), 26(4), 113-117

CODEN: DECRDP; ISSN: 0378-6501

PUBLISHER: Bioscience Ediprint Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Transforming growth factor (TGF)- β is believed to play a key role in the development of many autoimmune and malignant diseases, such as radiation and drug-induced organ disease. The aim of the present study was to determine mRNA production of TGF- β 1 in the lungs of C57Bl6 mice after

low-dose whole-body irradiation Control (irradiated) and irradiated angiotensin-converting enzyme (ACE) inhibitor-treated animals were simultaneously examined. The ACE inhibitor group received butylaminiperindopril for 9 days after irradiation (7 Gy) at a daily dose of 0.1 mg/kg per rectum. On day 9, all mice were sacrificed and the production of mRNA TGF- β 1 in lung tissue was determined semiquant. using reverse transcriptase polymerase chain reaction. In butylaminiperindopril-treated mice, a decrease in transcript of TGF- β 1 (to 59% in comparison with controls) was observed.

IT 107133-36-8, Butylaminiperindopril

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(butylaminiperindopril decreases transforming growth factor- β 1 mRNA production in lungs of C57BL6 mice after low-dose whole-body

irradiation)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 67 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:480742 HCAPLUS

DOCUMENT NUMBER: 131:149349
 TITLE: Drugs packaged by strip or press-through packaging and enclosed together with desiccants
 INVENTOR(S): Terao, Kazuyuki; Yoshikawa, Suehiro
 PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11206850	A2	19990803	JP 1998-16930	19980129
PRIORITY APPLN. INFO.:			JP 1998-16930	19980129

AB Solid drugs, which are packaged with a strip packaging or press-through packaging (PTP) material comprising a moisture-permeable and gas-barrier plastic sheet and an Al foil, are enclosed together with desiccant. The method prevents drugs which are instable to water, e.g. perindopril erbumine (I), etc., from deterioration due to moisture. Tablets of I were packaged with a poly(vinyl chloride) sheet and an Al foil by PTP and enclosed in an Al-laminated plastic film bag. The bag was stored at 40° and relative humidity 75% for 6 mo. Content of I in the tablets was 96.5%.

IT 107133-36-8, Perindopril erbumine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (strip or press-through packaging of drugs with moisture-permeable and gas-barrier plastic films and Al foil and enclosing them together with desiccants)


RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0
 CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
 CMF C4 H11 N



L17 ANSWER 68 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:480741 HCAPLUS

DOCUMENT NUMBER: 131:149348

TITLE: Drug desiccants and drugs stored together with the desiccants

INVENTOR(S): Terao, Kazuyuki; Yoshikawa, Suehiro

PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11206849	A2	19990803	JP 1998-16929	19980129
PRIORITY APPLN. INFO.:			JP 1998-16929	19980129
AB The desiccants are packed in a moisture-permeable and gas-barrier plastic bag. Solid drugs stored in a sealed container together with the desiccants are also claimed. The desiccants are useful for storing drugs instable to water and evaporable drugs. Tablets of perindopril erbumine (I) were stored in a glass bottle together with silica-alumina gel disk packed in a nylon-polyacrylonitrile laminated film at 40° and relative humidity 75% for 6 mo to show the content of I 97.3%. vs. 71.4% even after 2 mo for a control using a paper-packaged desiccant.				
IT 107133-36-8, Perindopril erbumine				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (drug desiccants packed in moisture-permeable and gas-barrier plastic film bag)				
RN 107133-36-8 HCAPLUS				
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)				
CM 1				
CRN 82834-16-0				
CMF C19 H32 N2 O5				


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 69 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:344860 HCAPLUS

DOCUMENT NUMBER: 130:357193

TITLE: Combination of angiotensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders

INVENTOR(S): Guez, David; Schiavi, Pierre; Levy, Bernard

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925374	A1	19990527	WO 1998-FR411	19980303
W: AU, BR, CA, CN, HU, JP, MX, NO, NZ, PL, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2771010	A1	19990521	FR 1997-14485	19971119
FR 2771010	B1	20030815		
CA 2310136	AA	19990527	CA 1998-2310136	19980303
CA 2310136	C	20040420		
AU 9868377	A1	19990607	AU 1998-68377	19980303
AU 740748	B2	20011115		
EP 1032414	A1	20000906	EP 1998-913813	19980303
EP 1032414	B1	20030507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9814885	A	20001003	BR 1998-14885	19980303
JP 2001523646	T2	20011127	JP 2000-520807	19980303

AT 239500	E	20030515	AT 1998-913813	19980303
NZ 504220	A	20030530	NZ 1998-504220	19980303
PT 1032414	T	20030829	PT 1998-913813	19980303
ES 2198708	T3	20040201	ES 1998-913813	19980303
ZA 9806673	A	19990204	ZA 1998-6673	19980727
NO 2000002479	A	20000512	NO 2000-2479	20000512
US 6653336	B1	20031125	US 2000-554715	20000518
PRIORITY APPLN. INFO.:			FR 1997-14485	A 19971119
			WO 1998-FR411	W 19980303

AB The use of a combination of the angiotensin converting enzyme inhibitor (IEC) with a diuretic to obtain pharmaceutical compns. for treating arteriole-capillary microcirculation disorders is disclosed. A tablet contained perindopril tert-butylamine (I) 2, indapamide (II) 0.625, colloidal silica 0.25, lactose 64.175, magnesium stearate 0.45, and microcryst. cellulose 22.5 mg. The efficacy of oral administration of 0.76 mg/kg/day I and 0.24 mg/kg/day II in rats is shown.

IT 107133-36-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination of angiotensin converting enzyme inhibitor with diuretic for treating microcirculation disorders)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 70 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:7800 HCAPLUS

DOCUMENT NUMBER: 130:57229

TITLE: Controlled release pharmaceutical preparation with ACE inhibitor as active agent

INVENTOR(S): Fischer, Wilfried; Klokckers, Karin; Oppelt, Renate

PATENT ASSIGNEE(S): Hexal Ag, Germany

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856355	A1	19981217	WO 1998-EP3536	19980612
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19724696	A1	19981224	DE 1997-19724696	19970612
CA 2295013	AA	19981217	CA 1998-2295013	19980612
AU 9883368	A1	19981230	AU 1998-83368	19980612
AU 736357	B2	20010726		
ZA 9805142	A	20000112	ZA 1998-5142	19980612
EP 994696	A1	20000426	EP 1998-933605	19980612
EP 994696	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
TR 9903069	T2	20000522	TR 1999-9903069	19980612
NZ 501726	A	20010928	NZ 1998-501726	19980612
JP 2002504108	T2	20020205	JP 1999-501625	19980612
AT 259637	E	20040315	AT 1998-933605	19980612
ES 2216296	T3	20041016	ES 1998-933605	19980612
NO 9906049	A	20000207	NO 1999-6049	19991208
US 6267990	B1	20010731	US 1999-460055	19991213
PRIORITY APPLN. INFO.:				
			DE 1997-19724696	A 19970612
			WO 1998-EP3536	W 19980612

AB The title preparation contains: (i) an initial dose of active agent and optional auxiliary agents, (ii) a 1st type of controlled-release pellet in which the active agent and optional auxiliary agents are coated, and (iii) a 2nd type of controlled-release pellet in which the active agent and optional auxiliary agents are also coated. The weight ratio of the masses of the coatings in (ii) and (iii) is (1:2)-(1:7). This preparation allows an almost immediate action of the ACE inhibitor (e.g. captopril) without a marked initial peak in blood level, and maintenance of a long-lasting therapeutic blood level of the drug thereafter with very little variation. Thus, pellets A were prepared containing captopril 5, Avicel (microcryst. cellulose) 3, and tablettose 2 mg. Pellets A (700 g) were coated with Opadry II 40.48 and H2O 250 g, followed by a 2nd coat containing Eudragit S 100 62.5, di-Bu phthalate 6.25, 96% EtOH 350.00, and H2O 87.5 g to produce

pellets B. Addnl. pellets A (700 g) were coated with Opadry II and H2O as above, followed by a coating of Eudragit S 100 192.5, di-Bu phthalate 19.25, 96% EtOH 1078, and H2O 269.5 g to produce pellets C. Pellets A 100, pellets B 700, and pellets C 700 g were dispensed into a gelatin capsule with a final captopril content of 150 mg.

IT 107133-36-8, Perindopril erbumine.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled release pharmaceutical preparation with ACE inhibitor as active agent)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 71 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:64980 HCAPLUS

DOCUMENT NUMBER: 124:97758

TITLE: Drug combination containing α -lipoic acid and cardiovascular agents

INVENTOR(S): Weischer, Carl; Ulrich, Heinz; Conrad, Frank; Schmidt, Karlheinz

PATENT ASSIGNEE(S): ASTA Medica AG, Germany
 SOURCE: Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4420102	A1	19951214	DE 1994-4420102	19940609
PRIORITY APPLN. INFO.:			DE 1994-4420102	19940609

AB A synergistic combination for treatment of cardiovascular and diabetes-associated disorders contains α -lipoic acid (or its enantiomers, derivs., or metabolites), ≥ 1 organic nitrate, Ca^{2+} antagonist, angiotensin-converting enzyme inhibitor, or oxyfedrine. Thus, 400-mg tablets were prepared from a mixture containing (S)- α -lipoic acid 250, oxyfedrine 40, microcryst. cellulose 760, starch 250, lactose 682.5, Mg stearate 15, and highly disperse SiO_2 2.5 g.

IT 107133-36-8, Perindopril-tert-butylamine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug combination containing α -lipoic acid and cardiovascular agents)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 72 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:620945 HCAPLUS

DOCUMENT NUMBER: 121:220945

TITLE: Pharmacokinetics of perindopril erbumine in rats. 2.

Blood level profile, distribution, metabolism and excretion after repeated oral administration

AUTHOR(S): Nakaoka, Minoru; Hakusui, Hideo; Jin, Yoshitaka; Tutumi, Syuichirou; Hironaka, Akiko; Hirano, Hiromi; Noguchi, Tomoyuki; Uohama, Katsumi; Takasaki, Michika; et al.

CORPORATE SOURCE: Developmental Research Laboratories, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan

SOURCE: Yakubutsu Dotai (1994), 9(2), 247-57

CODEN: YADOEL; ISSN: 0916-1139

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Pharmacokinetic studies on blood level, tissue distribution, metabolism and excretion of [¹⁴C]perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor, were performed in rats during and after repeated oral administration of at 0.5 mg/kg/day for 14 days. The blood levels of radioactivity reached a steady state after 5 days, and the equivalent concentration

on day 5 was 7.09 ng/mL. After repeated oral administration, the radioactivity was mainly distributed in the lungs, kidneys, liver and intestinal tract. The radioactivity was highest in the lungs, which contain high ACE activity, and reached a steady state after 14 days. Elimination of radioactivity from most of tissues was rapid. It is assumed that the accumulation of radioactivity in the plexus choroideus arose from high localization of ACE. The excretion rate in the urine and feces during repeated oral administration was almost constant. At 168 h after the last dose, the extent of excretion of radioactivity was 33.1% and 69.6% of the total dose in the urine and feces, resp. An active metabolite, perindoprilat, was found, which accounted for most of the radioactivity in the plasma, lungs, liver and kidneys, and also in the urine and feces.

IT 107133-36-8, Perindopril erbumine

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(perindopril erbumine pharmacokinetics and metabolism)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 73 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:620944 HCAPLUS

DOCUMENT NUMBER: 121:220944

TITLE: Pharmacokinetics of perindopril erbumine in rats. 1.

Plasma level profile, distribution, metabolism and excretion after single oral administration

AUTHOR(S): Suzuki, Wataru; Kato, Kinuyo; Nakaoka, Minoru; Hakusui, Hideo; Jin, Yoshitaka; Katami, Yoshiharu; Nogami, Takahiro; Shiina, Michiko; Otsu, Yuko; et al.

CORPORATE SOURCE: Developmental Research Laboratories, Daiichi

Pharmaceutical Co., Ltd., Tokyo, Japan

SOURCE: Yakubutsu Dotai (1994), 9(2), 235-46

CODEN: YADOEL; ISSN: 0916-1139

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Pharmacokinetic studies on plasma level, tissue distribution, metabolism and excretion of [¹⁴C]perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor, were performed in fasting male rats after single oral administration at 0.5 mg/kg. The radioactivity in plasma reached a maximum equivalent to 88 ng/mL after 1 h, and the elimination half-lives were 2.1 h (2-8 h) and 34 h (24-72 h). After single oral administration, the radioactivity was rapidly distributed to tissues, reaching maximum levels after 1 h in most tissues. After 8 h, a high level of radioactivity was detected in the lungs, pituitary gland, intestines, kidneys and aorta, due to high localization of ACE in these tissues. After 168 h, the level of radioactivity was reduced in all tissues. After 168 h, the radioactivity excreted in the urine and feces accounted for 39.7% and 58.7% of the dose, resp. Biliary excretion of radioactivity was 31.2% within 48 h. The total recoveries from urine, bile and carcass accounted for 75.4% of the dose, suggesting good gastrointestinal absorption. An active metabolite, perindoprilat, was found, which accounted for most of the radioactivity in the plasma, lungs, liver and kidneys, and also in the urine and feces. A

linear dose dependency of the pharmacokinetics was observed

IT 107133-36-8, Perindopril erbumine

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(perindopril erbumine pharmacokinetics and metabolism)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 74 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:118595 HCAPLUS

DOCUMENT NUMBER: 112:118595

TITLE: Some syntheses of tritium biochemicals at high specific radioactivity: radiosyntheses of ACE inhibitors, 5-HT1A and dopamine receptors radioligands
Pichat, L.

AUTHOR(S): CEA - CEN Saclay, Gif-sur-Yvette, 91191, Fr.

CORPORATE SOURCE: Synth. Appl. Isot. Labelled Cpd. 1988, Proc. Int.


SOURCE: Symp. (1989), Meeting Date 1988, 21-6. Editor(s): Baillie, Thomas A.; Jones, John Richards. Elsevier: Amsterdam, Neth.

CODEN: 56OXA8

DOCUMENT TYPE: Conference

LANGUAGE: English

GI



AB A lecture with 9 refs. Synthesis of tritium labeled biochems. I and II as potent inhibitors of angiotensin converting enzyme (ACE) and III (OR = 5-OMe, 8-OMe) as D2 receptors is described.

IT 125650-71-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiotensin converting enzyme inhibitors)

RN 125650-71-7 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, labeled with tritium, [2S-[1[R*(R*)],2α,3aβ,7aβ]]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 125650-70-6

CMF C19 H32 N2 O5

CIL XH-13


Absolute stereochemistry.



CM 2

CRN 75-64-9

CMF C4 H11 N



IT 117770-59-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(tritiation of)

RN 117770-59-9 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)-3-butenyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 117770-58-8

CMF C19 H30 N2 O5


Absolute stereochemistry.



CM 2

CRN 75-64-9



CMF C4 H11 N



L17 ANSWER 75 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:515749 HCAPLUS
DOCUMENT NUMBER: 111:115749
TITLE: Preparation of perindopril via acylation of

perhydroindolecarboxylate with N-
 [(ethoxycarbonyl)butyl]alanine
 INVENTOR(S): Vincent, Michel; Baliarda, Jean; Marchand, Bernard;
 Remond, Georges
 PATENT ASSIGNEE(S): ADIR, Fr.
 SOURCE: Eur. Pat. Appl., 25 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 308341	A1	19890322	EP 1988-402339	19880916
EP 308341	B1	19901212		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2620709	A1	19890324	FR 1987-12896	19870917
FR 2620709	B1	19900907		
CA 1336348	A1	19950718	CA 1988-577078	19880907
DK 8805151	A	19890318	DK 1988-5151	19880915
DK 171470	B1	19961111		
AU 8822362	A1	19890323	AU 1988-22362	19880916
AU 608363	B2	19910328		
JP 01110696	A2	19890427	JP 1988-232125	19880916
JP 05043717	B4	19930702		
ZA 8806932	A	19890530	ZA 1988-6932	19880916
US 4914214	A	19900403	US 1988-245446	19880916
AT 59047	E	19901215	AT 1988-402339	19880916
CA 1338015	A1	19960130	CA 1991-616239	19911128
PRIORITY APPLN. INFO.:			FR 1987-12896	A 19870917
			CA 1988-577078	A3 19880907
			EP 1988-402339	A 19880916
OTHER SOURCE(S):	MARPAT 111:115749			
GI				



AB Preparation of perindopril via acylation of perhydroindolecarboxylate with N-[(ethoxycarbonyl)butyl]alanine. The title compound (I), useful as an antihypertensive (no data), is prepared, e.g., via N-acylation of perhydroindole derivative II (preparation given) with (S,S)-HO₂CCHMeNHCHPrCO₂Et (III). II.p-MeC₆H₄SO₃H (preparation given) was condensed with III in EtOAc containing Et₃N, 1-hydroxybenzotriazole, and dicyclohexylcarbodiimide to give, after deprotection and treatment with Me₃CNH₂, I.Me₃CNH₂.

IT 107133-36-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, via acylation of perhydroindole derivative with N-[(ethoxycarbonyl)butyl]alanine)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1.

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 76 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:477846 HCAPLUS

DOCUMENT NUMBER: 111:77846

TITLE: Industrial preparation of (2S,3aS,7aS)-perhydroindole-2-carboxylic acid as intermediate for antihypertensive perindopril

INVENTOR(S): Vincent, Michel; Baliarda, Jean; Marchand, Bernard; Remond, Georges

PATENT ASSIGNEE(S): ADIR, Fr.

SOURCE: Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 308339	A1	19890322	EP 1988-402337	19880916
EP 308339	B1	19920506		

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

FR 2620703	A1	19890324	FR 1987-12900	19870917
FR 2620703	B1	19911004		
DK 8805149	A	19890318	DK 1988-5149	19880915
AU 8822361	A1	19890323	AU 1988-22361	19880916
AU 618752	B2	19920109		
ZA 8806931	A	19890530	ZA 1988-6931	19880916
US 4935525	A	19900619	US 1988-245352	19880916
JP 02191251	A2	19900727	JP 1988-232123	19880916
AT 75735	E	19920515	AT 1988-402337	19880916
ES 2033450	T3	19930316	ES 1988-402337	19880916
US 4954640	A	19900904	US 1990-462797	19900110
PRIORITY APPLN. INFO.:			FR 1987-12900	A 19870917
			EP 1988-402337	A 19880916
			US 1988-245352	A3 19880916

OTHER SOURCE(S): CASREACT 111:77846; MARPAT 111:77846
GI



AB The title compound (I), useful as an intermediate for antihypertensive perindopril, was prepared from indolecarboxylic acid derivs. II (R = H, lower alkyl). Esterification of II (R = H) in EtOH containing H₂SO₄, reduction with Sn in EtOH containing HCl, saponification, and resolution gave

(S)-indoline-2-carboxylic acid (III). Hydrogenation of III over Rh under H₂ at 60° gave (2S,3aS,7aS)-octahydroindole-2-carboxylic acid.

IT 107133-36-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate for, octahydroindolecarboxylic acid as)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 82834-16-0

CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

L17 ANSWER 77 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:204950 HCAPLUS

DOCUMENT NUMBER: 110:204950

TITLE: Gas chromatography-mass spectrometry of perindopril and its active free metabolite, an angiotensin convertase inhibitor: choice of derivatives and ionization modes

AUTHOR(S): Tsacanas, Christos; Devissaguet, Michele; Padieu, Prudent

CORPORATE SOURCE: Cent. Spectrom. Masse, Fac. Med., Dijon, F-21033, Fr.


SOURCE: Journal of Chromatography (1989), 488(1), 249-65

CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Perindopril (I), a perhydroindole compound and a novel class of angiotensin convertase inhibitor, after oral administration leads to an active metabolite by de-esterification of the Et ester. Routine biol. measurements are currently done using a radioimmunol. assay, but a mass fragmento-graphic method was developed using plasma spiked with the drugs, which were then derivatized to the iso-Bu ester heptofluorobutyramide and assayed using ammonia neg. chemical ionization. Levels of 100 pg/mL were assayed. However, isobutanol derivatization provoked partial transesterification of the Et ester of the parent drug into the diisobutyl ester derivative, which corresponds to the active metabolite. A second method of derivatization to stable trimethylsilyl esters preserved the original Et ester of the parent drug. Despite the lower ionization yields, the mass fragmentog. method was sensitive and accurate enough to work satisfactorily at the 2 ng/mL level in spiked plasma, which is the level

found currently in patients.

IT 107133-36-8, S-9490-3

RL: ANT (Analyte); ANST (Analytical study)

(determination of, in blood plasma of humans by gas chromatog.-mass spectrometry, derivatization and ionization modes for)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N



L17 ANSWER 78 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:631529 HCAPLUS

DOCUMENT NUMBER: 109:231529

TITLE: Synthesis of S9490-3 [U-14C-cyclohexyl] 1-[(2S)2-[(1S)1-(ethoxycarbonylbutyl)amino]-1-oxopropyl]-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid tert-butylamine salt and S9780 [U-14C-cyclohexyl] 1-[(2S)2-[(1S)1-(carboxybutyl)amino]-1-oxopropyl]-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid and of [3,4-3H-butylamino]S9490-3 and [(3,4-3H-butylamino)S9780

AUTHOR(S): Pichat, L.; Tostain, J.; Gomis, J. M.; Coppo, M.; Moustier, A. M.; Vincent, M.; Remond, G.; Portevin, B.; Laubie, M.

CORPORATE SOURCE: CEN Saclay, Gif sur Yvette, 91191, Fr.


SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals
(1988), 25(5), 553-68
CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal

LANGUAGE: French

OTHER SOURCE(S): CASREACT 109:231529

GI



AB The title ^{14}C -labeled compds. I (* signifies the uniform labeling of the cyclohexane ring with ^{14}C) and II were prepared from aniline- $U\text{-}^{14}\text{C}$ in several steps. The title ^3H -labeled compds. were also prepared. The latter synthesis involved the tritiation of an allylglycine residue. The title compds. are potent inhibitors of angiotensin-converting enzyme.

IT 117770-49-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)

RN 117770-49-7 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, labeled with carbon-14, [2S-[1[R*(R*)],2 α ,3 α ,7 α]]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 117770-48-6

CMF C19 H32 N2 O5

CIL XC-14


Absolute stereochemistry.



CM 2

CRN 75-64-9

CMF C4 H11 N



IT 117770-59-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tritiation of)

RN 117770-59-9 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)-3-butenyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 117770-58-8

CMF C19 H30 N2 O5

Absolute stereochemistry.



CM 2

CRN 75-64-9
CMF C4 H11 N

L17 ANSWER 79 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:87332 HCAPLUS

DOCUMENT NUMBER: 108:87332

TITLE: New convertase inhibitors

AUTHOR(S): Wiecek, Andrzej; Grzeszczak, Wladyslaw

CORPORATE SOURCE: Klin. Nefrol., Slaska Akad. Med., Katowice, 40-027, Pol.

SOURCE: Polskie Archiwum Medycyny Wewnetrznej (1986), 76(5-6 /11-12/), 291-7

CODEN: PAMWAL; ISSN: 0032-3772

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Polish

AB A review, with 27 refs., of inhibitors of angiotensin-converting enzyme, including MK 521, ramipril (Hoe 498), perindopril (S-9490-3), pivalopril (RHC 3659(S)), CI 906, CI 607, CGS 13945, CGS 13934, CGS 14824A, and L 681176.

IT 107133-36-8, S-9490-3

RL: BIOL (Biological study)
(angiotensin-converting enzyme inhibition by)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0


CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 75-64-9
CMF C4 H11 N



L17 ANSWER 80 OF 80 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:113304 HCAPLUS
 DOCUMENT NUMBER: 106:113304
 TITLE: Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer
 AUTHOR(S): Richer, C.; Thuillez, C.; Giudicelli, J. F.
 CORPORATE SOURCE: Serv. Pharmacol. Clin., Hop. Bicetre, Le Kremlin-Bicetre, 94275, Fr.
 SOURCE: Journal of Cardiovascular Pharmacology (1987), 9(1), 94-102
 CODEN: JCPCDT; ISSN: 0160-2446
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The effects of three doses (4, 8, and 16 mg) of perindopril tert-butylamine salt (I) [107133-36-8], a new angiotensin I converting enzyme [9015-82-1] inhibitor, on systemic blood pressure, heart rate, brachial and carotid artery flow and diameter (assessed by the pulsed Doppler technique), forearm vascular resistance, plasma converting enzyme and renin [9015-94-5] activities, and plasma aldosterone [52-39-1] were investigated in the normal volunteer and compared with those of a placebo over a 24-h period following oral drug intake in a double-blind, cross-over trial. I dose-dependently decreased plasma converting enzyme activity, an effect that peaked at 3-4 h and persisted up to at least 48 h. Plasma renin activity increased for 12 h and plasma aldosterone was slightly decreased. Systemic blood pressure and heart rate were not drug-affected but I dose-dependently augmented brachial and carotid artery flow, indicating an increase in peripheral arterial compliance. These vasodilating effects, which lasted up to 10 h after drug intake, affected both large arteries and arterioles, the latter being more sensitive, however, and were more marked in the muscular resistance vessels.

IT 107133-36-8

RL: PRP (Properties)

(converting enzyme inhibition and cardiovascular effects of, in humans)

RN 107133-36-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0

CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9

CMF C4 H11 N

